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3. Abbreviations  
 
Abbreviation Full name 
ALD Fructose bisphosphate aldolase 
AMPK AMP-activated protein kinase 
AR Amphiregulin 
ATP Adenosine triphosphate 
BrdU Bromodeoxyuridine 
BSA Bovine serum albumine 
BTC Betacellulin 
CoA Coenzyme A 
CTMP Carboxy terminal modulating protein 
DCFH Dichloro fluorescein 
DMEM Dulbecco’s modified eagle’s medium 
DMSO Dimetyl sulfoxide 
EDTA ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
ENO  Enolase 
EPR Epiregulin 
ERK Extracellular signal-regulated kinases 
ETC Electron transport chain 
FACS Fluorescence-activated cell sorting 
FAD Flavin adenine dinucleotide 
FBS Foetal bovine serum 
FCCP Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
FdG  Fluorodeoxyglucose 
FH Fumarate hydratase 
FSC Forward scatter  
G6P Glucose 6-phosphate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GBM Glioblastoma multiforme 
GLUT Glucose transporter 
GPI Glucose phosphate isomerase 
Grb2 Growth factor receptor-bound protein 2 
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HB-EGF Heparin-binding epidermal growth factor 
HIF   Hypoxia inducible factor 
HK  Hexokinase 
IMM Inner mitochondrial membrane 
IMS Inter membrane space 
JAK Janus kinase 
LDH Lactate dehydrogenase 
m2-PK pyruvate kinase M2 
MAPK Mitogen-activated protein kinase 
mDNA Mitochondrial DNA 
MEK MAPK/ERK kinase 
MRDR Mito tracker deep red  
mTOR Mamalian target of rapamycin 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAD Nicotinamide adenine dinucleotide 
NaDOC Sodium deoxylate 
NAO Nonyl acridine orange  
NO Nitrogen oxide 
OMM Outer mitochondrial membrane 
PDK1 PIP3-dependent kinase 1 
PET  Positron-emission tomography 
PFK Phosphofructo kinase 
PGK   Phosphoglycerate kinase 
PGM Phosphoglycerate mutase 
PH Pleckstrin homology  
PI3K Phosphoinositide 3-kinase 
PIP2 Phosphatidylinositol 3,4 -bisphosphate  
PIP3 Phosphphatidyl-inositol 3,4,5- bisphosphate  
PK Pyrovate kinase 
PTEN Phosphatase and tensin homologue deleted on chromosome 10 
PYK  Pyruvate kinase 
rictor Rapamycin – insensitive companion of mTOR 
ROS Reactive oxygen species 
Rsk Ribosomal S6 protein kinase 
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RTK Tyrosine kinase receptors 
SDH Succinate dehydrogenase  
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SHIP SH2-containing inositol phosphatase 
SOS Son of sevenless 
SSC Side scatter  
STAT Signal transducers and activator of transcription 
TGF-α Transforming growth factor α   
TMRM Tetramethyl rhodamine methyl ester  
TPI  Triosephosphate isomerase 
tRNA Transfer RNA 
UCP Uncoupling protein 
VDAC  Voltage-dependent anion channel 
VHL Von Hippel-Lindau protein 
WT Wild type 
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4. Introduction 
 
4.1 Cancer 
The life cycle of a normal cell is strictly controlled by multiple check points and regulatory 
factors. Cancer cells on the other hand contain defects in the regulatory machinery that govern 
cell proliferation and homeostasis, which in turn may lead to tumor formation [1]. For the 
majority of cancer cells a number of characteristic features seem to contribute to the tumor 
development. These physiological changes include; insensibility to growth-inhibitory signals, 
inhibition of programmed cell death, self-sufficiency in growth signals, sustained 
angiogenesis, limitless replicative potential and tissue invasion and metastasis [1]. In addition 
to uncontrolled cell proliferation, most tumors are also characterized by specific changes in 
energy metabolism. Tumor cells tend to take up large amounts of glucose and secrete lactate. 
The fact that cancer cells may generate many of their needed growth signals reduces their 
dependence of stimuli from other tissues [1] . Some of these signals can be sensed by the 
epidermal growth factor receptor (EGFR) and may contribute in the regulation of tumor cell 
metabolism and proliferation.  
 
4.2 Glucose catabolism and cellular bioenergetics 
 
4.2.1 Glycolysis 
Glycolysis is the process where glucose is transformed into 2 molecules of pyruvate in order 
to be utilized for energy production. This pathway contains 10 enzymatic steps and takes 
place in the cytosol [2]. The glycolysis is divided into two phases (Figure 4.1). In the 
preparatory phase 2 molecules of adenosine triphosphate (ATP) are invested to raise the free 
energy state within the adapted glucose molecule. This energy gain is used for the production 
of 2 nicotinamide adenine dinucleotide (NADH) and 4 ATP molecules in the payoff phase. 
The overall equation of glycolysis is: 
Glucose + 2 NAD+ + 2 ADP + 2Pi → 2 pyruvate + 2 NADH + 2H+ + 2 ATP + 2 H2O 
The further fission of pyruvate is normally determined by the oxygen level. If oxygen is 
absent (anaerobic conditions) pyruvate is reduced to lactate in a process catalyzed by lactate 
dehydrogenase (LDH). Under aerobic conditions (oxygen present) pyruvate are translocated 
into mitochondria and completely oxidized to CO2 and H2O, and the reduction of pyruvate to 
lactate is prevented. Findings by Pasteur showed an elevated use of glucose when oxygen 
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were absent compared to aerobic conditions, and this phenomenon has been named the 
Pasteur effect [3].   
 
 
Figure 4.1. The glycolytic pathway in normal (left) versus malign cells (right). The glucose molecules are 
unable to diffuse through the plasma membrane, and therefore depend on glucose transporters (GLUTs) to enter 
the cell. Once in the cytosol, glucose enters the glycolytic pathway and is converted to pyruvate. (Alternatively, 
at rest periods glucose enters the glycogenesis where it is converted to glycogen for long time storage).  
Malign cells tend to have a modified metabolism, and the most notorious alteration of energy metabolism is an 
elevated glycolytic capacity [4]. This is obtained by overexpression of glycolytic enzymes and transporters as 
illustrated in this figure. The yellow spheres represent levels of enzymes/transporters in healthy cells, while blue 
spheres represent tumor cells conditions. Here, GLUT = glucose transporter, HK = hexokinase, GPI = glucose 
phosphate isomerase, PFK-1 = phospho fructokinase-1, ALD = fructose bisphosphate aldolase, TPI = 
triosephosphate isomerase, GAPDH = glyceraldehyde phosphate dehydrogenase, PGK = phosphoglycerate 
kinase, PGM = phosphoglycerate mutase, ENO = enolase, PYK = pyruvate kinase , LDH = lactate 
dehydrogenase [4].  
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4.2.2 Mitochondrial ATP synthesis 
The mitochondria are known as the cellular power plants and are the home of the citric acid 
and electron transport chain (ETC). Central elements of mitochondrial structure and function 
are described in Figure 4.2.  
 
Figure 4.2 Mitochondrial structure and function. The mitochondrial matrix is enclosed by two lipid 
membranes, an outer mitochondrial membrane (OMM) and an inner mitochondrial membrane (IMM). The 
pocket between the membranes is known as the inter membrane space (IMS). The IMM is folded by 
invaginations called cristae, which gains a greater surface area. The citric acid cycle is located in the matrix, 
while the ETC is located in the inner mitochondrial membrane.  
Mitochondria contain small circular DNA molecules referred to as the mitochondrial genome. The 16,6 kb 
mitochondrial DNA (mtDNA) is responsible for encoding 13 of the proteins found in the ETC,  but also 2 
rRNAs and 22 tRNAs necessary for mitochondrial gene translation. In addition the genome contains a non 
coding region called the D-loop [5]. Mitochondrial proteins involved in replication, transcription and translation 
are under control by nuclear DNA. The D-loop region of the mtDNA has been termed “the mutational hot spot” 
and mutations in this region have been found in most examined tumors [6]. As mammalian mtDNA lack histones 
and introns it is tenfold more vulnerable to mutations and oxidative damage than nuclear DNA [7].  
 
4.2.2.1 Citric acid cycle 
Before entering the citric acid cycle the pyruvate produced during glycolysis is irreversible 
oxidized to acetyl CoA. This is a key molecule in the energy metabolism also being the end 
product yielded by fatty acid- and amino acid degradation. Acetyl CoA enters the citric acid 
cycle and is converted to oxaloacetate through eight sequential reactions (Figure 4.3). The 
total energetic outcome from one acetyl CoA molecule oxidized by the cycle is 1 FADH2, 1 
GTP (equivalent to 1 ATP) and 3 NADH.  
Recent discoveries of mutations in the nuclear genes of the citric acid cycle enzymes 
succinate dehydrogenase (SDH) and fumarate hydratase (FH) has provided proof that primary 
inherited abnormalities in mitochondria can cause tumors [8]. 
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Figure 4.3 Overview of the citric acid cycle.  
 
4.2.3 Mitochondrial respiration – oxidative phosphorylation  
The ETC is located in the cristae of the inner mitochondrial membrane and contain 4 protein 
complexes (Complex I - IV) that are linked together by the electron transporters coenzyme Q 
and cytochrome c (Figure 4.4). The ETC is the terminal step of the energy metabolism and 
here the remaining energy of oxidized nutrients are used to drive the synthesis of ATP via 
ATP synthase (complex V). 
 
Electrons are loaded into the chain by the electron transporters NADH and FADH2. NADH 
donates electrons to complex I (NADH dehydrogenase) and FADH2 to complex II (succinate 
dehydrogenase). The electrons are transferred stepwise between the complexes and finally 
donated to molecular oxygen at complex IV (cytochrome oxidase enzyme), forming 2 
molecules of water. As the electrons move through the chain, protons are simultaneously 
translocated from the matrix to the IMS. The proton release leads to an increased proton 
gradient across the IMM, making the matrix negatively charged. These factors are collectively 
termed the proton motive force. This mitochondrial membrane potential (ΔΨm) is a hallmark 
of respiratory function and is often modified in malign cells [9]. Further, the proton motive 
force drives the movement of protons into the mitochondrial matrix through Complex V. As 
the protons cross the IMM their free energy is donated and used for the synthesis of ATP from 
ADP and Pi. The synthesised ATP is transported out of the mitochondria through 
ANT/VDAC channels [10]. 
 
Uncoupling is the process when the link between proton motive force and ATP synthesis is 
broken and protons freely leak through the IMM. Under such conditions energy is released as 
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heat instead of being utilized for ATP production. Uncoupling is a natural occurring event 
carried out by uncoupling proteins (UCPs), but can also be initiated by chemical uncouplers 
such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) [11].  
 
Figure 4.4.  The electron transport chain. The figure presents the movement of electrons between the different 
complexes and the formation of a proton gradient used for ATP synthesis (see text for further details). Inhibitors 
of the different ETC complexes are shown at the top. 
 
The ETC is associated with the production of reactive oxygen species (ROS). Under stressful 
conditions an elevated ROS production may occur, leading to damage of cellular compounds 
[12]. ROS can also influence mitochondrial function, thus lowering the respiratory energy 
production.  
A modified metabolic status can be sensed by AMP-activated protein kinase (AMPK) [13] 
which may alter the mitochondrial biogenesis through elevated expression of mitochondrial 
proteins and enhanced mitochondrial proliferation. ROS production and mitochondrial mass 
are measurable properties that can be impaired in tumor cells. 
 
4.3 Tumor cell metabolism 
 
4.3.1 Warburg effect   
Normal cells have a finely tuned balance between glycolysis and oxidative phosphorylation 
for ATP production. In most malign cells this balance is disrupted with an increased 
glycolytic activity and a down regulation of the mitochondrial respiration even in the presence 
of oxygen (aerobic glycolysis) [14]. Under such conditions pyruvate is reduced to lactate with 
the excess lactate being excreted from the cell. These findings were observed by Otto 
Heinrich Warburg back in 1924, and have later been termed the “Warburg effect”. Warburg 
postulated that these changes in metabolism were the fundamental cause of cancer [15]. 
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Today, more than 8 decades later, the mutation in tumor suppressor genes and oncogenes are 
known to be the fundamental triggers in carcinoma development [16].  There are several 
hypotheses why the “Warburg effect” occurs in tumor cells; i) it may be an adaption to the 
low-oxygen environment that can be found in tumors, ii) a result of cancer genes shutting 
down the mitochondria because of their contribution in the apoptotic program or iii) simply 
because the mitochondria are damaged in cancer [4]. 
The fact that most primary and metastatic human cancers have a high uptake and consumption 
of glucose can be used in clinical application. The utilization of the glucose analogue tracer 
fluorodeoxyglucose (FdG) in positron-emission tomography (PET) gains sensitive 
information of tumor development [17].  
   
In contrast to normal cells an overexpression of glycolytic enzymes and glucose transporters 
are often found in malignant cells. The increased glycolytic flux has been proposed to be a 
metabolic strategy of tumor cells to ensure survival and growth when facing hypoxic 
conditions[14]. 
 
4.3.2 HIF-1 – A trigger of glycolytic abnormalities  
Activation of hypoxia inducible factor-1 (HIF-1)  is believed to be a main mechanism 
triggering the enhanced glycolysis in tumor cells [4]. Being a transcription factor for 
glycogenic genes, HIF-1 promotes the expression of the enzymes hexokinase (HK), 
phosphofructokinase 1 and 2  (PFK-1, PFK-2), aldehyde dehydrogenase (ALD), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), 
enolase (ENO), pyruvate kinase (PYK) and lactate dehydrogenase (LDH) (Figure 4.1). All 
together this stimulates the glycolytic flux [18, 19]. 
HIF-1 consists of the two subunits HIF-1α and HIF-1β where the α-subunit determines the 
stability of the complex. At aerobic conditions HIF-1α is actively led to degradation by the 
von Hippel-Lindau protein (VHL) at the proteasome, while in lack of oxygen HIF-1α 
becomes highly stable. At aerobic conditions HIF-1α may be induced by growth factors 
(EGFR), ROS (reactive oxygen species), NO (nitrogen oxide) and cytokines [20, 21]. 
Mutations in the von Hippel-Lindau protein have been found in some aggressive tumors 
leading to an enhanced HIF-1 concentration [21].  
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4.3.3 Glycolytic enzymes and transporters 
Tumor cells depend on their ability to survive under stressful and variable conditions. In fast 
growing tumors hypoxic areas with limited blood supply are often seen, and here the level of 
glucose, oxygen and other substrates may be low [4]. 
The enhanced glycolytic activity within tumor cells is believed to occur due to the increased 
expression of glycolytic enzymes and transporters [14]. A large number of studies have 
shown that the protein isoforms hexokinase II (HK-II), GLUT-1, phosphoglucomutase 
(PGM), pyruvate kinase M2 (m2-PK), lactate dehydrogenase-A and isoforms of the lactate 
transporter are frequently overexpressed in multiple cancers [4].  
 
4.3.3.1 Hexokinase 
Hexokinase (HK) is the first enzyme in the glycolytic pathway and is responsible for the 
transformation of glucose to glucose 6-phosphate (G6P) (Figure 4.1). Four different isoforms 
of HK are found in mammalian cells, named HK-I to HK-IV [22] . The isoforms differ in 
kinetic properties and have tissue specific localization. HK-II has shown to be the 
predominant isoform in fast growing tumor cells, except from brain tumors where HK-I is 
overexpressed [23]. 
HK-II is able to bind to the outer mitochondrial membrane through a specific interaction with 
the voltage-dependent anion channel (VDAC). This protects the kinase from degrading 
proteases and enables to give a direct access to the newly synthesized ATP from ATP 
synthase [24]. Studies indicate that the HK-II - VDAC complex formation may interfere with 
the function of the pro-apoptotic protein Bax. When binding VDAC, Bax is responsible for 
the release of cytocrome c and other apoptotic mitochondrial proteins under stress conditions 
[25]. Therefore HK-II may have an additional role as an inhibitor of apoptosis.  
The accumulation of a product may decrease the further reaction through a negative control 
mechanism. This effect is seen in the glycolysis with G6P  being a potent inhibitor of HK-I, 
HK-II and HK-III [22]. The binding of HK to the mitochondria was therefore believed to be a 
mechanism to bypass the G6P inhibition.  
 
4.3.3.2 GLUT 
Glucose molecules lack the ability to diffuse through the cellular membrane and depend on 
ATP-driven transporters to enter the cytoplasm (Figure 4.1). This transport is carried out by 
trans-membrane glucose transporters (GLUTs), a family of proteins consisting of at least 13 
members [26]. In order to utilize the increased glycolytic capacity for energy production, 
malignant tissues depend on an enhanced income of glucose. Mutations in the genome leading 
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to overexpression of the GLUTs are found in a variety of cancers and is considered to be 
critical for tumor maintenance [14]. Studies indicate that the tumor GLUT activity is 10-12 
folds higher compared to non-tumorigenic cells (Figure 4.1) [27].  
 
4.3 EGFR structure and function 
The epidermal growth factor receptor (EGFR) is located at the cell surface and is activated 
when binding its ligand epidermal growth factor (EGF) (Figure 4.5). EGFR belongs of the 
ErbB family of tyrosine kinase receptors (RTK) which consists of four members; EGFR 
(ErbB-1), ErbB-2, ErbB-3 and ErbB-4. All these proteins have an extracellular ligand binding 
site, a hydrophobic trans-membrane domain and an intracellular domain containing tyrosine 
kinase activity. The main difference is found in the extracellular domain where the four 
receptors show a different ligand binding specificity [28].   
 
The EGFR binding ligands can be divided into two groups; i) EGFR specific ligands that 
include EGF, transforming growth factor α (TGF-α) and amphiregulin (AR). ii) Ligands with 
a dual specificy for both EGFR and ErbB-2 receptors. This group include heparin-binding 
growth factor (HB-EGF), betacellulin (BTC) and epiregulin (EPR) [29]. 
The ErbB receptors ligands may be secreted either by the receptor containing cell itself 
(autocrine secretion) or by surrounding cells (paracrine secretion) [28].  
 
When binding their ligands the ErbB receptors may form homo-dimers by cross binding to a 
similar protein or hetero-dimers by linking to a different receptor of the ErbB family. After 
dimerization the receptors are often endocytosed and linked to the adaptor protein, c-cbl, 
which targets it for degradation. This regulatory process helps limiting the signalling outcome 
of the ligand binding [30, 31].   
 
4.4 EGFR signalling –Down stream effects 
A variety of downstream proteins may be activated upon binding of EGF to its receptor. 
EGFR takes part in a multiple cellular events and is known to trigger the three well known 
pathways; i) Ras-Raf-MEK-ERK-pathway, ii) PI3 kinase/Akt-pathway and iii) JAK/STAT-
pathway [32] (Figure 4.5). The PI3 kinase/Akt pathway has been proven to be an important 
regulator of metabolism and glycolysis in cancer cells [33] and is of particular interest for the 
presented project.  
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Figure 4.5. The downstream effects of EGFR activation.  
 
4.4.1 PI3 kinase/Akt-pathway 
The Akt signalling pathway may be engaged by receptor tyrosine kinases such as EGFR. 
Akt is a threonine-serine kinase and is a member of the “cAMP-dependent, cGMP-dependent 
protein kinase C”- family of kinases [34]. The protein consist of three isoforms; Akt1, Akt2 
and Akt3, and all contain a N-terminal pleckstrin homology (PH) domain and a C-terminal 
kinase domain [35]. Akt is a well known pro survival factor, and downstream of the protein a 
branched network of more than 3000 substrates has been identified. Akt is in part responsible 
for the increased resistance to apoptosis, the uncontrolled cell proliferation and the altered cell 
metabolism which are characteristic features of transformed cells [36]. Additionally Akt has 
been shown to be involved in cellular processes as transcription, translation, cell growth and 
angiogenesis (Figure 4.6) [37]. Akt also positively regulate the activity of the protein 
synthesis regulator mammalian target of rapamycin (mTOR) [38].  
 
Figure 4.6. The multiple roles of Akt in cellular responses.  
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Upon activation, EGFR attracts the lipid kinase phosphoinositide 3-kinase (PI3K). PI3K 
consist of two subunits that must be linked together to yield an active form. As mentioned 
earlier the growth receptor contains a phosphorilated tyrosine (Y) residue that may serve as a 
docking site, this time for the PI3K p85 subunit. Once bound the p110 subunit is recruited to 
the complex. When activated, PI3K phosphorylate inositol ring 3'OH groups in 
phosphatidylinositol 3,4 -bisphosphate (PIP2) and adds an inositol group to the molecule 
forming phosphphatidyl-inositol 3,4,5- bisphosphate (PIP3) [39]. PIP3 recruit a diversity of 
signalling proteins with PH domains to the plasma membrane where they are activated [40]. 
Among these proteins are PDK1 (PIP3-dependent kinase 1) and Akt. The binding of Akt to 
PIP3 is thought to provoke conformational changes in Akt, resulting in the exposure of its two 
main phosphorylation sites Thr 308 and Ser 473. Akt is then phosphorylated by PDK1 and the 
mTOR/rictor-complex [41].  
 
An important negative regulator of the PI3K/Akt pathway is the lipid phosphatase 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN). This enzyme reverses 
the process by removing the 3-phosphate from PIP3 to produce PIP2. In certain cancers the 
gene encoding PTEN may be mutated, giving a decreased PTEN function. As a consequence 
the level of PIP3 rises, leading to an increased Akt activation [42]. Additional negative 
regulators are the phosphatase SH2-containing inositol phosphatase (SHIP) and the newly 
discovered carboxy terminal modulating protein (CTMP). The importance of SHIP and 
CTMP in PI3K-Akt regulation is unclear since there have been no reports of altered levels in 
human cancers [43]. 
 
4.4.2 AMPK 
AMP-activated protein kinase (AMPK) is a protein system acting as a sensor of cellular 
energy, a system found within all genetic determined eukaryotic cells [13]. The protein 
complex is activated by an increase in the cellular AMP/ATP ratio that occurs due to 
metabolic stresses that accelerate ATP consumption or interfering with the ATP production 
[13] . When activated, AMPK initiates catabolic processes responsible for ATP production 
and turns of ATP-consuming pathways (proliferation and cell growth) through modulation of 
multiple down-stream proteins [13]. As seen in figure 4.7 AMPK takes part in down-
regulation of protein synthesis and up-regulating of fatty acid oxidation. AMPK is also an up-
stream activator of the p53 stress sensor [44].  
AMPK is a heterotrimer consisting of the three subunits α, β and γ. The α-subunit has 
catalytic activity, and the β subunit contains a glycogen binding site while the γ-subunit binds 
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the inhibitory ATP or the activating AMP at two regulatory sites [13]. Binding of AMP to 
AMPK causes an allosteric change that activates the complex and also promotes further 
phosphorylation of the AMPK α-subunit by the kinase LKB1. This phosphorylation is 
necessary for the full activation of AMPK [45].  
 
In cancer cells, the rapid growth and disordered angiogenesis can create hypoxic areas with 
limited nutrition supply. Under such stressful conditions AMPK can be activated. Recent 
studies have shown that AMPK control mechanisms contribute in the regulation of apoptosis 
and growth in tumor cells[46] .Paradoxically, AMPK activation has been suggested to be 
necessary for tumor cell survival and expansion, at least in the short turn by preventing further 
cell growth before nutrients are supplied by raised angiogenesis [47].    
 
Figure 4.7 AMPK regulation. Akt activation of mTOR is believed to be regulated by Akt through at least two 
distinct pathways. Akt is capable of activating mTOR direct by phosphorylation and inhibition of the negative 
mTOR regulator tuberous sclerosis complex 2 (TSC2) and Rheb. Recent data has shown an additional pathway 
in which Akt regulates mTOR activation, namely through inhibition of the TSC2 activator AMPK. By 
stimulating ATP production, Akt decreases the AMP/ATP ratio and therefore reduces AMPK activity [38]. It has 
been suggested that AMPK can directly phosphorylate and inactivate mTOR, but this has not yet been verified 
[48]. AMPK binding of AMP also facilitates phosphorylation of Thr 172 by LKB1, and this further enhances 
enzyme activity [45]. AMPK is an upstream regulator of acetyl-CoA carboxylase (ACC) and is therefore capable 
of upregulating the fatty acid oxidation. Activated AMPK has proven to be an initiator of the stress signal p53 
[44].  
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4.5 Alternative EGFR modulated metabolic regulators  
The link between the tumor suppressor p53 and cancer development and progression is well 
established [49]. During the last years the role of p53 has emerged, being an important 
metabolic regulator of both the glycolytic and mitochondrial respiratory pathways. p53 has 
been shown to be involved in upregulation of HK and having an inhibitory effect on PFK-1 
and PGM in the glycolysis [50-52]. Studies have shown that p53 is able to promote the 
aerobic respiration by an increased expression of Complex IV subunits in the ETC [53] and to 
affect the glucose uptake by binding GLUT1 and GLUT4 [54]. 
 
The signalling pathways Ras-Raf-MEK-ERK and JAK/STAT may also take part in EGFR 
mediated metabolic regulation through their controlled expression of various genes [55, 56].  
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5. Aims 
 
 
Tumor cells tend to have a manipulated energy metabolism, presented by an elevated 
glycolytic activity and decreased mitochondrial respiration. This behaviour can be caused by 
several factors such as oncogene signalling, hypoxia, mitochondrial dysfunction or over-
expression of metabolic enzymes and proteins.  
The objective of the presented study was to determine if EGFR represents a possible 
regulatory link between cellular proliferation and energy metabolism in cancer cells. 
In this study two different U87 glioblastoma cells were studied; a wild type cell line and a 
mutated cell line expressing the constitutively active EGFR vIII protein. By measuring 
multiple cellular- and mitochondrial properties we also wanted to examine if the mitochondria 
play different roles within the two samples. The following aims can be highlighted;  
1. Determine if altered EGFR signalling affects cell proliferation. 
2. Investigate if EGFR vIII expression changes energy metabolism within cancer cells.  
3. Examine if pharmacological manipulation of the metabolism can change the growth 
potential of the cancer cells. If this is the case, may EGFR vIII involved? 
4. Investigate possible interactions between EGFR with major signalling factors such as Akt 
and AMPK. 
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6. Materials 
 
6.1 Chemicals 
Chemicals Abbreviation/ Chemical formula 
MW, 
g/mol Supplier 
2-deoxy-D-glukose C6H12O5 164,16 Sigma 
2-Mercaptoethanol C2H12OS 78,1 Merck 
30 % akrylamid/bis solution, 37,5:1 - - Merck 
Ammonium persulphate APS, H8N2O8S2 228,2 BioRad 
Aprotinin from bovine lung C284H432N84O79S7 6511,44 Sigma  
Bovine serum albumin, 1,49mg/ml BSA - Sigma-Aldrich 
Carbonyl cyanide 4-(trifluormetoksy)-
phenylhydrazone 
FCCP , 
C10H5F3N40, 
254,17 Sigma 
Cytocrome c Cyt c 12500 Sigma 
Digitonin, ~50% (TLC) C56H92O29 1229,31 Fluka 
Dimethyl sulphoxide DMSO, (CH3)2SO 78,1 Merck 
Disodium hydrogen phosphate Na2HPO4 141,96 Sigma 
Dimetylsulfoxid HYBRI-MAX® DMSO, (CH3)2SO4 78,1 Sigma 
Dulbecco’s Modified Eagle’s Medium  
(+ 4500 mg glucose/L, without L-
glutamin) 
DMEM - Sigma 
Dulbecco’s Modified Eagle’s Medium 
without phenol red 
(+ 4500 mg glucose/L, with L-glutamin) 
DMEM - Gibco 
Ethanol, 96% C2H5OH 46,1 Vinmonopolet 
Ethylene glycol tetraacetic acid 
 
EGTA 380,4 Sigma 
Foetal bovine serum FBS - 
PAA: The Cell 
Culture Company 
Formaldehyde, 37% solution CH2O 30,03 Sigma 
Freeze dried milk (0,6% fat) Mlk - Marvel 
Glutamate C5H8NO4Na 169,1 Sigma 
Glycine, > 99,7 % C2H5NO2 75,07 Merck 
Glycerol > 99,5% C3H8O3 92,1 Fluka 
HEPES C8H18N2O4S 238,3 Sigma 
Hydrocloric acid HCl 36,5 Merck 
Hydrogen peroxide solution, 30% in H2O H2O2 34,01 Sigma 
Hydrazine H2NNH2·H2O 32,04 Sigma 
K-lactobionate C12H22O12 358,3 Fluka 
Leupeptin hemisulphate salt C20H38N6O4. 1/2H2SO4 475,59 Sigma 
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Luminol, >97 % C8H7N3O2 177,16 Sigma 
L-glutamine C5H10N2O3 146,14 Sigma 
Magnesium chloride  MgCl2 · 6H2O 203,3 Scharlau 
Malic acid C4H6O5 134,1 Sigma 
Methanol CH3OH 32,0 Merck 
Monopotassium phosphate KH2PO4 136,1 Merck 
NAD+ - 663,43 Fluka 
N,N,N’,N’-tetrametyletylendiamid C6H16N2, TEMED 116,2 BioRad 
Nonidet P40 NP40, (C6H4O)nC14H22O - Sigma 
Oligomycine - 800 Sigma 
p-Coumaric acid HOC6H4CH=CHCO2H 164,16 Sigma 
Penicillin/Streptomycin (100x) 
PenStrep, 
C16H17N2NaOS:C42H84N14O26S3 
- 
PAA: The Cell 
Culture Company 
Phenylmetanesylphonyl fluoride PMSF, C7H7FO2S 174,19 Sigma 
Ponceau S C22H12N4Na4O13S4 760,57 Sigma 
Rotenone C23H22O6 394,42 Sigma 
Sodium chloride  NaCl 58,44 Merck 
Sodium deoksycholate NaDOC,C24H39O4· Na 414,6 Calbiochem 
Sodium orthovandat Na3VO4 183,91 Sigma 
Sodium dodecylsulphate  SDS, C12H25O4SNa 288,4 Merck 
Sucrose C12H22O11 342,3 Roth 
Taurine C2H7NO3S 125,1 Sigma 
Trizma® base, >99,9 % titrering TRIS, C4H11NO3 121,14 Sigma 
Trypan Blue C23H24N6O14S4Na4 960,81 Sigma 
TWEEN® 20 - - Sigma 
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6.2 Solutions and buffers 
 
6.2.1 Standard culture medium 
Solution Ingredients Final concentration 
DMEM medium DMEM with 4,5g/L glucose, without L-Glutamine  89 % (v/v) 
 Foetal Bovine Serum*  9 % (v/v) 
 L-glutamine  1 % (v/v) 
 Penicillin/Streptomycin (100x)  1 % (v/v) 
* Heat inactivated for 30 minutes at 56oC  
 
6.2.2 PBS solution 
Solution Ingredients Final concentration 
NaCl 8 g 
KCl 0,2g 
Na2HPO4 x H2O 2g 
KH2PO4 0,4g 
H20 To 1 litre  
PBS x1 
NaOH To pH 7,3 
 
6.2.3 Cryogenic medium 
Solution Ingredients Final concentration 
Cryogenic  DMEM with 4,5g/L glucose, without L-glutamine 70 % (v/v) 
medium Foetal bovine serum (FBS) 20 % (v/v) 
 DMSO (Dimetyl sulfoxide 200mg/ml) 10 % (v/v) 
 
6.2.4 Buffers for cell lysation 
Solution Ingredients Final concentration 
NP40-RIPA buffer NP40 (Nonidet P40) 1 % (v/v) 
 10% SDS 1 % (v/v) 
 NaDOC (Sodium deoxylate) 0,5 % (w/v) 
 1M TRIS, pH 7,4 5 % (v/v) 
 5M NaCl 3 % (v/v) 
 H2O 87 % (v/v) 
RIPA buffer* Aprotinin 1µg/µl 0,1 % (v/v) 
 Leupeptin 1µg/µl 0,1 % (v/v) 
 Natrium Vanadat 100µM 1,0 % (v/v) 
 PMSF (phenylmethylsulponylfluoride) 1,0 % (v/v) 
 NP40-RIPA buffer 97,8 % (v/v) 
*Must be freshly made since the PMSF is only active for 30 minutes after the mix of the 
reagents. 
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6.2.5 Gels and solutions for SDS-PAGE and Western Blotting 
Solution Ingredients Final concentration 
10% Separating gel 30% Acrylamide/bis solution 10 % (w/v) 
 1,5mM TRIS pH 8,8 375mM 
 H2O 40,5 % (v/v) 
 SDS 10% 0,1 % (w/v) 
 Ammonium persulphate 10% 0,05 % (w/v) 
 TEMED 0,05 % (w/v) 
4% Stacking gel 30% Acrylamide/bis solution 4 % (w/v) 
 0,5mM TRIS pH 6,8 125mM 
 H2O 60 % (v/v) 
 SDS 10% 0,1 % (w/v) 
 Ammonium persulphate 10% 0,05 % (w/v) 
 TEMED 0,04 % (w/v) 
Sample buffer 95% Glycerol  42 % 
 20% SDS  8 % (w/v) 
 1,5m TRIS pH 6,8 279 mM 
 2-mercaptoetanol 4 % (v/v) 
 BTB ~0,1 mg/ml (w/v) 
10x Running buffer TRIS 250 mM 
 Glycine 1,92 M 
 0,1% SDS 1% (w/v) 
 H2O  
1x Transfer buffer Trizima base 25 mM 
 Glycine 192 mM 
 Methanol 20 % (v/v) 
 H2O 80 % (v/v) 
TBS-T TRIS-HCl, pH 8,0 25 mM 
 NaCl 125 mM 
 Tween-20 0,1% (v/v) 
Blocking buffer TBS-T 97 % (v/v) 
 Dried fat free milk 3 % (w/v) 
Detection reagent A 100mM TRIS-HCL pH 8,5 100 mM 
 Luminol  254 mM 
 p-Coumaric acid (Enhancer)  15,5 mM 
Detection reagent B 100mM TRIS-HCL pH 8,5 100mM 
 30% H2O2 solution 1,8 mM 
Incubation buffer BSA 0,5 g 
 PBS x1 100 ml 
 
6.2.6 Solutions for lactate determination  
Solution Ingredients Final concentration 
Reagent A 163,64 mM Hydrazine 0,79 % (v/v) 
 10,55 mM NAD+ 7,78 % (v/v) 
 64,21 mM Glycine 6,42 % (v/v) 
 H2O 50,0 % (v/v) 
 5M NaOH (adjusted to pH 9)  0,50 % (v/v) 
 H2O 35,0 % (v/v) 
Reagent B LDL (Lactate dehydrogenase) 13 enzyme units 
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6.2.7 Solutions used for the BrdU assay 
Solution Ingredients Final concentration 
BrdU labelling reagent (10mM) BrdU labelling 
solution DMEM with 4,5g/L glucose, without L-Glutamine 
Anti-BrdU-POD Anti-BrdU-POD 
stock solution milliQ H2O (1,1ml) 
Anti-BrdU-POD stock solution Anti-BrdU-POD 
working solution Antibody dilution solution 
As described in the 
manifacturers 
instructions 
 
6.2.8 Solutions used for the MTT assay 
Solution Ingredients Final concentration 
MTT stock solution MTT 5mg 
 PBS 1ml 
SDS-HCl solution SDS 1g 
 0,01M HCl 10 ml 
As described in the 
manifacturers 
instructions 
 
6.2.9 Solutions for oxygraph measurements 
Solution Ingredients Final concentration 
EGTA 0,190 g (0,5mM) 
MgCl2 6H2O 0,610 g (3 mM) 
K-lactobionate 120 ml of 0,5M stock (60 mM) 
Taurine 2,502 g (20 mM) 
KH2PO4 1,361 g (10 mM) 
HEPES 4,77 g (20mM) 
Sucrose 37,65 g (110 mM) 
BSA 1 g (1g/L) 
Miro5 
H2O To 1 litre 
 
6.3 Molecular mass and size standards 
Standard Range Supplier 
Precision Plus Protein all blue standard (pre-stainded) 10-250 kDa BioRad 
MagicMark™ XP Western Protein Standard 20-220 kDa Invitrogen 
 
6.4 Antibodies used for protein determination 
6.4.1 Primary antibodies used for flow cytometry 
Antibody Host Working dilution Supplier 
Anti-phospho-Akt (Ser 473) Rabbit 1:100 Cell signalling 
Anti-phospho-Akt (Thr 308) Rabbit 1:100 Cell signalling 
Anti-Akt Rabbit 1:100 Cell signalling 
Anti-phospho-AMPK α (Thr 172) Rabbit 1:50 Cell signalling 
Anti-AMPK α Rabbit 1:50 Cell signalling 
Anti-phospho-AMPK β (Ser 108) Rabbit 1:100 Cell signalling 
Anti- AMPK β Rabbit 1:50 Cell signalling 
Anti-Acetyl-CoA Carboxylase Rabbit 1:400 Cell signalling 
Anti-phospho-Acetyl-CoA 
Carboxylase (Ser 79) Rabbit 1:25 Cell signalling 
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6.4.2 EGFR vIII antibody used for flow cytometry and western blotting 
Antibody Host Working dilution Supplier 
EGFR vIII Mouse 1:200 (flow cytometry) 1:500 (western blotting) 
Hrvoje 
Miletic 
 
6.4.3 Secondary antibodies used for flow cytometry and western blotting 
Antibody Host Working dilution Supplier 
Goat anti rabbit Alexa 647 Goat 1:1000 Invitrogen 
Anti mouse horshradish 
peroxidise conjugated Goat 1:5000 Biorad 
Anti mouse APC Goat 1:1000 Molecular probes 
 
6.5 Fluorescent probes for Flow cytometry analysis 
Fluorescent probe Laser Maximum excitation 
Maximum 
emission Detector Supplier 
NAO (acridine orange 10-
nonyl bromide) 488 495nm 519nm FL-1 Invitrogen 
ROS (CM2H2DCFDA) 488 495nm 517nm FL-1 Invitrogen 
TMRM (Tetramethyl 
Rhodamine Methyl Ester) 488 549nm 577nm FL-2 Invitrogen 
 
6.6 Commercial kits 
Kit Supplier 
Pierce® BCA protein assay kit Thermo scientific 
Vybrant® MTT Cell Proliferation Assay Kit Molecular Probes® 
Cell proliferation ELISA, BrdU (colorimetric) Roche 
AlamarBlue® Assay BIOSOURCE™ 
Mito Tracker Deep Red 633 Invitrogen 
 
6.7 Computer software 
Software Supplier 
DigiRed Microplate Instrumentation Control 
FlowJo FlowJo 
BD CellQuest™ BD Biosciences 
Quantity One BioRad 
KCjunior Bio-Tek instruments 
UltraView  Ultra View 
ImageSuite  Microsoft 
DatLab 4  Oroboros 
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6.8 Consumables 
Consumable Supplier 
Cell culture flasks Sarstedt, Nunc 
96 welled adhesion test plates Sarstedt, Nunc 
Acrodisc® syringe filters PALL corporations 
1-25ml pipettes Sarstedt 
Syringes Sabre 
15/50 ml tubes Sarstedt, Nunc, VWR 
Microsentrifuge tubes Brand 
1-1000µl pipettes Gilson, Finntip 
Glass bottom microwell dishes MatTec corporations 
  
6.9 Technical equipment 
Equipment Supplier 
BD FACSCalibur™ Flow Cytometer BD biosciences 
Centrifuge 5810R Eppendorf 
Fluor-S™ Multimager BioRad 
Haake W26/Haake DC10 Thermo 
Hetomaster Shake Comfort 
Hotplate Kervel 
Lamin Air airflow cabinet Nuaire 
Vacusafe comfort Vacusafe 
HeraCell 150 Heracell 
UVM340 ELISA reader Asys 
SpectraMAX, GeminiEM Molecular Devices Corporation 
CKX31SF light microscope Olympus 
Roller mixer Stuart 
Nikon Eclipse TS100 light microscope Nikon 
Transsonic T310 sonicator Elma® 
Mettler AT200 Mettler 
CP2202S Sartonius 
691 PH-meter Metrohm 
OROBOROS Oxygraph-2k Oroboros instruments 
Drieblock DB Techne 
Locator 8 Plus Thermolyne 
PowerPac HC BioRad 
PowerPac 1000 BioRad 
KL-2 Edmund Bukler 
Rotamax 120 Heidolph 
Mini-protean 3 electrophoresis cell for SDS-PAGE BioRad 
Mini-trans blot cell for western blot BioRad 
Magnet Strirrer Cenco 
MS2-Minishaker IKA® 
Minispinn Eppendorf 
Stir CB161 Stuart 
Pipetboy Comfort Integra Biosciences 
Heracell 150 Heraeus 
Bürker Assistent 
Zeiss LSB 510 Meta, confocal microscope Carl Zeiss 
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7. Methods 
 
7.1 Cell lines 
7.1.1 U87 glioma cells 
The U87 human glioblastoma cell line has an epithelial morphology and was a kind gift from 
Hrvoje Miletic. Glioblastoma multiforme (GBM) is the most common and aggressive brain 
tumor found in adults. GBM accounts for 52 percent of primary brain tumors and has a 
median patient survival time of 12 months from diagnosis [57]. EGFR is the most frequently 
altered gene within GBM, and is found to be overexpressed in 40-50 percent of the occasions. 
For nearly 50 percent of these cases the mutant EGFR variant III (EGFR vIII) is co-expressed, 
and the detection of EGFR vIII is often associated with poor patient prognosis [58, 59] 
Compared to the WT, EGFR vIII lack a region at the extracellular receptor domain making it 
unable to bind EGFR binding ligands. However, due to this structural manipulation, the 
receptor is constantly phosphorylated and able to activate downstream signaling pathways 
[60]. The mutated form is believed to act, at least in part, through different signaling cascades 
than the WT, and this may account for the increased malignancy for EGFR vIII expressing 
cells [61]. Since the EGFR vIII is only found in tumor cells it can prove to be an ideal target 
for anti cancer therapy.  
 
7.1.2 3T3 fibroblast cells 
3T3 cells are the standard fibroblast cell line and were originally obtained from mouse 
embryo tissue [62]. In the proliferation experiments the 3T3 cells were used as a reference. 
 
7.2 Growth medium and cell maintenance  
The adhesive glioma and fibroblast cells were grown in cell culture flasks and split every 
other day. The cells were kept in a tissue culture incubator in a humidified environment at 
37oC / 5% CO2 in a Dulbecco’s Modified Eagle’s Medium (DMEM) added 10 % heat 
deactivated foetal bovine serum (FBS), 1 % L-glutamine and 1 % penicillin/Streptomycin 
(100x). 
When maintaining the cells, the medium was removed and the cells were rinsed with PBS to 
remove dead cells and old medium. 4ml trypsin-EDTA (0,25%) and 3ml PBS was added to 
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detach the cells. The trypsin reaction was inactivated by adding an equivalent amount of 
culture medium. The cells were transferred to a 15 ml tube and centrifuged at 800rpm for  
4 minutes (the supernatant was wasted and the cell pellet re-suspended) before approximately  
3 million cells were added to the fresh medium in a cell culture flask. 
 
7.3 Cryogenic preservation and storage 
When preparing the cells for cryogenic preservation, cells were detached as previously 
described, counted and re-suspended in cryogenic medium to give a concentration of 1-3 x 
106 cells/ml. 1 ml of the cell suspension were distributed into cryogenic vials. To avoid 
frigidity shock the cryogenic vials were placed in an isopropanol box lowering the 
temperature 1oC per minute and stored in a -80ºC fridge for approximately 24 hours. For long 
time storage the cells were kept in liquid nitrogen at -170ºC. 
Upon thawing, the preserved cells were gently heated to 37oC. The cell suspension was 
resuspended in culture media and incubated in a 75 ml culture flask in a tissue culture 
incubator at 37oC / 5% CO2. The following day the culture medium was changed and the cells 
further maintained as previously described[63].  
 
7.4 Oxygraph 
The oxygraph is an excellent instrument for determination of oxygen consumption for various 
samples as cells, isolated mitochondria or tissue homogenates. Two samples can be run at the 
time as the instrument contains two separate chambers with oxygen sensors (electrodes). 
Before starting the experiment the cambers must be properly closed and all air bubbles 
removed to make sure that all oxygen consumed is delivered from the sample medium. 
Samples added to the chambers are kept at constant temperature and stirred to get an equal 
oxygen distribution. Being directly connected to the Oroboros DatLab4 computer software, 
the oxygen sensors can deliver real-time updates on the consumption rates and oxygen levels 
in the chambers. By sequential adding substrates and inhibitors of the ETC it is possible to 
analyze various aspects of mitochondrial function. The agents added during the experiment 
are listed in table 7.1. 
 
 
 
 
  Methods 
 31
Table 7.1 Agents added to the samples during oxygraph analysis 
Chemical Function 
Oligomycin Inhibitor of the ATP synthase. Used to determine the proton 
leakage through the inner mitochondrial membrane.   
FCCP FCCP is an uncoupler that allows proton flow through the 
mitochondrial matrix without ATP synthesis. Used to characterize 
the maximum respiratory capacity.  
Rotenone Inhibitor of NaDH-dehydrogenase at complex I by blocking the 
proteins electron transport properties. Used to determine complex I 
contribution in the ATP production. 
 
7.5 Lactate assay 
According to the Warburg legacy many cancer cells have an up-regulated glycolysis and an 
enhanced lactate production [15]. The lactate production indicates whether the malign cell 
uses glycolysis or mitochondrial respiration as their primary energy source. Therefore, lactate 
measurements are helpful when determining the nature of tumor cells.  
 
Lactate secretion was determined by analyzing the cellular culture medium where cells had 
been grown for 48 hours. The collected medium was diluted with fresh DMEM culture 
medium without FBS to 6 different concentrations; 100%, 50%, 20%, 10%, 5% and 2.5% 
(used media: fresh media). 5 lactate standard solutions with the concentrations of 4mM, 3mM, 
2mM, 1mM and 0.5mM were made and 20µl of all samples were transferred to a 96 welled 
test plate previously loaded with 170µl Reagent A solution. The hydrazine within this reagent 
destroys the pyruvate and allows complete oxidation of all lactate molecules. To ensure this, 
NAD+ was provided in excess. The lactate concentration in the sample is proportional to the 
raise in absorbance as NAD+ is reduced to NADH. The test plate was screened at 340nm 
using an ELx808 Ultra Microplate ELISA Reader. 10µl lactate dehydrogenase (Reagent B = 
LDH) is added to the samples and the plate is incubated at room temperature for 60 minutes. 
The lactate dehydrogenase oxidizes the lactate back to pyruvate. Finally the 96 welled test 
plate is screened at the ELISA reader at 340 nm a second time. Calculations were carried out 
using the KCjunior computer software. 
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7.6 Cell proliferation assays 
There are several proliferation assays that can be used in calculation and determination of cell 
growth properties. Here BrdU, alamarblue and MTT were compared to find the most suited 
assay for further analyses. For all the proliferation assays, measurements for U87 WT, U87 
EGFR vIII and 3T3 cells were carried out. Exponentially growing cells were trypsinized, 
counted and diluted accordingly. For all assays the cells were plated with densities of 1000, 
2000, 3000, 5000, 7000, 10000 and 15000 cells/well in a flat-bottomed 96-welled plate and 
stored for 24 hours at 37oC / 5% CO2 in a cell incubator. All cells were dissolved in 200µl 
culture media. Pure culture media was added to some wells to serve as a background. To 
include a negative control pure medium was treated in the same way as the cells. All 
absorbance measurements were carried out on a UVM340 ELISA reader and calculations 
were made using DigiRed computer software. 
 
7.6.1 BrdU 
Bromodeoxyuridine (BrdU) is a synthetic pyrimidine analogue that is incorporated into the 
DNA instead of thymidine in proliferating cells. BrdU specific antibodies detect the 
incorporated nucleoside, and by doing this measure replicated cells. The reaction product is 
quantified by colorimetric measuring the absorbance at the respective wavelength at an 
ELISA reader. The ability of BrdU to replace thymidine during DNA replication can cause 
genetic mutations, and it is therefore a potentially health hazard.   
 
20µl 100µM BrdU labeling solution was added to each well before the plate was incubated 
for 4 hours at 37oC / 5%. The culture media/labeling solution was removed and 200µl/well 
Fix Denat solution was added and cells incubated for 30 minutes at room temperature. The 
Fix Denat solution was tapped and 100µl/well anti-BrdU-POD working solution was added 
before the plate was incubated for 90 minutes at room temperature. The antibody solution was 
discarded and the wells rinsed 3 times using PBS. 100µl/well substrate solution was added 
and the samples were incubated at room temperature until color development is sufficient for 
photometric detection. Finally, the sample absorbance was measured at 370nm. 
All steps in the assay were carried out according to the manufacturers’ instructions.  
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7.6.2 Alamarblue 
The assay contains an oxidation-reduction (REDOX) indicator that both changes color and 
fluoresces in response to cellular growth. The metabolic activity within the growing cell 
results in a chemical converting of reasazurin (the active ingredient in alamarblue) to 
resorufin. A continued growth of the cells maintains a reduced environment, while growth 
inhibition gains an oxidized environment. Growth related reduction causes the REDOX 
indicator to transform from the oxidized form (blue, non-fluorecent) to the reduced form (red, 
fluorescent). These cellular changes can be detected using an ELISA reader or a fluorescence 
spectrophotometer.     
 
20µl/well alamarblue was added and the plate was further stored in the incubator. 
Colorimetric measures were accomplished after 2, 3, 4 and 24 hours at 570nm and 600nm 
respectively.  
The percent of reduced AlamarBlue is determined by using equation 7.1: 
 100A)(A)(
A)(A)(
WellControlNegativeC
WellTestC
12RED21RED
21OX12OX
OX
RED ×λ′λε−λ′λε
λλε−λλε=  
Equation 7.1. Used for the calculation of % reduced AlamarBlue from absorbance measurements.  
 
Where, 
CRED  = concentration of the reduced form AlamarBlue 
COX  = oxidized form of AlamarBlue 
εRED = molar extinction coefficient of Alamar Blue reduced form 
εOX  = molar extinction coefficient of Alamar Blue oxidized form 
A  = absorbance of test wells 
A’  = absorbance of negative control wells 
λ1  = 570 nm 
λ2  = 600 nm 
 
A fluorescent measurement was carried out 4 hours after alamarblue addition at 530nm 
excitation wavelength and at 590nm emission wavelength using a SpectraMAX, GeminiEM 
fluorescence spectrophotometer. 
 
7.6.3 MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is one of the 
most versatile and popular assays used for cell growth rate determination. The assay includes 
the transformation of the water soluble MTT to purple, insoluble formazan crystals, a reaction 
carried out by viable cells.  
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Since the presence of phenol red in the final assay samples can seriously affect the results, a 
blank DMEM culture medium was used (DMEM without phenol red). After incubation the 
medium was removed and replaced with fresh culture medium before 20µl MTT stock 
solution was added. The stained cells were incubated for 4 hours at 37oC / 5% CO2 in a cell 
incubator, before 100µl/well SDS-HCl solution were added. The plate is thoroughly mixed 
using a pipette before incubated at 37oC/5% CO2 for another 18 hours. After incubation the 
samples are mixed before the absorbance is measured at 570nm on an UVM340 ELISA 
reader. 
 
7.7 Flow cytometry 
Flow cytometry is an analytic technology where particles or cells are suspended in a steam of 
fluid and transported through a laser beam. This technique can measure size, internal 
complexity, relative granularity and relative fluorescence intensity of particles/cells within the 
size range of 0.2 – 150 micrometers. Because flow cytometry can do multi parametric single 
cell analysis with a high throughput, it is a powerful tool within cell/particle characterization.   
 
The flow cytometer has three main systems, fluidics, optics and electronics. The fluidic 
system is responsible for the transports of the particles to the laser beam for detection. In the 
optics lasers illuminate the particles and optical filters direct the scattered lights to the 
appropriate detectors. The electronic system detects the light signal and converts it into 
electric signals that analyzed by computer software.  
 
When a sample is loaded into the flow cytometer it is surrounded by a sheath of fluid. The 
sample pressure is higher than the sheth fluid pressure, accelerating the particles and keeping 
them in the centre of the fluid stream. This process is known as hydrodynamic focusing and 
allows just a single cell/particle to be illuminated at the time, making it possible to observe 
heterogeneous differences in a cell population. Scattered light is measured using different 
detectors. Light passing through the sample is collected by the forward scatter (FSC) and is 
used for particle/cellular size determination. Side scattered light (SSC) is proportional to cell 
granularity or internal complexity. This refracted light is picked up in a 90o angle to the laser 
beam. If the sample is stained with a fluorescent marker the emitted fluorescence is collected 
and guided to the appropriate detector depending on the wavelength of the emitted light (see 
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illustration in figure 7.1 for details). 
 
Figure 7.1. Optical bench diagram of the FACS Calibur flow cytometer. The figure is taken from the FACS 
Calibur instructions manual. 
 
7.7.1 Cell characterization  
The expression of EGFR vIII protein was determined by staining the cells with an EGFR vIII 
antibody. First, the cells were detached and counted as previously described and 4 samples 
were made for each cell line. 2x105 cells in culture medium were transferred to micro-
centrifuge tubes and added 1 ml PBS-0.2% BSA. The tubes were centrifuged at 700xG for 5 
minutes, before aspirating the supernatant. The pellet are gently re-suspended in100µl EGFR 
vIII (1:200) in cold PBS-0.2% BSA, before incubated at room temperature for 30 minutes. 
The sample are rinsed using 1 ml cold PBS-0.2% BSA and centrifuged as described above. 
The supernatant is removed and the washing step repeated. The cells are re-suspended in 
100µl goat-anti mouse APC secondary antibody (1:1000) in cold PBS-0.2% BSA and 
incubated for 30 minutes at room temperature in the dark. The samples are rinsed two more 
times and the samples re-suspended in 300µl cold PBS-0.2% BSA before FACS analysis. The 
antibody stained cells were detected in FL-4 (far red emission). Three different samples were 
measured for each cell line: 
1. A control solution containing unstained cells. 
2. A control solution only added secondary antibody 
3. A solution stained with primary and secondary antibody. Here two parallels were 
made for each cell line.  
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7.7.2 Determination of mitochondrial properties by flow cytometry 
Three fluorescent probes were used to measure mitochondrial characteristics for the wild type 
and mutated cell lines; Nonyl Acridine Orange (NAO), CM2H2DCFDA (ROS) and 
Tetramethyl Rhodamine Methyl Ester (TMRM). For all samples the cells were detached and 
the cell density adjusted to 1x106 cells/ml in growth medium. 
 
NAO is an appropriate marker of the inner mitochondrial membrane in whole cells. NAO 
binds to the negatively charged phospholipid cardiolipin which is only found in mitochondrial 
membranes. This can be used to measure mitochondrial content and observe mitochondrial 
biogenesis.  
The NAO probes were added to give a final concentration of 200nM. In addition a NAO 
control solution containing 1mM FCCP was made and all samples were incubated for 15 
minutes at 37oC / 5% CO2. The NAO stained cells were cooled down on ice before 
centrifuged at 800rpm for 4 minutes. The supernatant was removed and the pellet re-
suspended in 500µl cold PBS. The samples were transferred to FACS test tubes and the 
fluorescent emission was detected in FL-1 using the flow cytometer. 
 
CM2H2DCFDA (ROS) is widely used to measure oxidative stress in cells. ROS is resistant to 
oxidation, but is de-acetylated by intracellular esterases when taken up by cells. This leads to 
the formation of the more hydrophilic, nonfluorescent dye dichlorofluorescin (DCFH). DCFH 
is then rapidly oxidized to form a two-electron oxidation product, the highly fluorescent DCF 
in a reaction with the oxidizing species (H2O2).  
The ROS probe is made by diluting CM2H2DCFDA by DMSO to yield a final concentration 
of 5µM within the samples. A ROS control solution containing 100µM H2O2 was also made. 
The samples are incubated at 37oC for 30 minutes before fluorescence was detected in the FL-
1 detector at the flow cytometer. 
 
TMRM is a cationic, mitochondrial selective probe that can be used as a cytofluorometric 
method for analyzing the mitochondrial membrane potential (ΔΨm). Being a key indicator of 
mitochondrial function the characterization of ΔΨm allows for an accurate determination of 
mitochondrial bioenergetics and cellular metabolism. 
TMRM were added to the cell samples to give a final concentration of 200nM. In addition a 
control solution added 1mM FCCP was made for each cell line. The samples were incubated 
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for 30 minutes at 37oC before transferred to FACS test tubes. The emitted fluorescence was 
detected in the FL-2 detector using the flow cytometer. 
 
10 000 cells/sample was analyzed using a BD FACS calibur™ flow cytometer and processed 
to the BD CellQuest computer software. Further analyses were done using FlowJo flow 
cytometry software. 
 
Table 7.2 Probes and central information used for determination of mitochondrial properties  
Probe Concentration Incubation time Temperature Control solution Detector 
NAO 200nM 15 min 37oC 2µl 1mM FCCP FL-1 
ROS 5µM 30 min 37oC 1µl 100µM H2O2 FL-1 
TMRM 200nM 30 min 37oC 2µl 1mM FCCP FL-2 
 
7.7.3 Fixation of cells used for antibody staining 
Cells were detached and collected as previous described, centrifuged for  
4 minutes at 800 rpm before briefly re-suspended in 1ml 3.7% formaldehyde in PBS. The 
cells were fixated for 10 minutes before chilled on ice for 1 minute. The cell suspensions were 
pelleted by centrifugation, the fix was removed and the cells were permeabilized by adding 
ice-cold 100% methanol to a final concentration of 90 % methanol. After 30 minutes 
incubation on ice the cells were ready for antibody staining.  
Upon antibody staining 0.5·106 cells were transferred into each assay tube. 2 ml incubation 
buffer was added to the tubes and rinsed by centrifugation. The rinsing procedure was 
repeated before the cells were re-suspended in 100µl incubation buffer and blocked for 10 
minutes at room temperature. The primary antibody was added at appropriate dilution to the 
assay tubes and incubated at 60 minutes at room temperature. (Antibody dilutions can be seen 
in section 6.4 in Materials.) The cells were rinsed by centrifugation as previously described. 
Finally the secondary antibody diluted in incubation buffer was added to each tube and cells 
are incubated for 30 minutes at room temperature. Cells were rinsed and re-suspended in 0.5 
ml PBS before analyzed at the FACS Calibur flow cytometer.     
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7.8 Cell lysis, protein determination, SDS-PAGE & Western Blotting 
7.8.1 Cell lysis and protein determination 
Approximately 1x107 cells were transferred to a 15 ml test tube and centrifuged at 800 rpm 
for 4 minutes. The medium was removed and the pellet re-suspended in PBS before the 
centrifugation were repeated. Afterwards the cells were put on ice and dissolved in 500µl 
RIPA lysating buffer. The samples were incubated on ice for 2 minutes before centrifuged at 
4000rpm for 5 minutes. The cell lysate was transferred to autoclaved eppendorf tubes and the 
protein concentration determined by using a Pierce© BCA Protein Assay Kit and spectro-
photometric analysis (562nm at the UVM340 ELISA reader).  
 
The protein concentration of the protein samples were determined by a set of protein 
standards. These standards were made by BSA (bovine serum albumine) diluted in RIPA 
buffer to yield final BSA concentrations of 2000, 1500, 1000, 750, 500, 250, 125, 25 and 0 
µg/ml. The lysate of the two cell lines were diluted by RIPA buffer to give final lysate 
concentrations of 100%, 50%, 20%, 10% and 5%. 25µl of the standard solutions and protein 
samples were translocated to a 96 welled plate.  
200µl working reactant solution from the protein assay kit was added to each well and the 
plate was mixed thoroughly on a plate shaker for 30 seconds, before covered and incubated 
for 30 minutes at 37oC. The plate was cooled to room temperature before the absorbance was 
measured at 562 nm using the UVM340 ELISA reader.  
The absorbance values found were used to draw a standard curve for the BSA protein 
standard. This data was used together with the protein sample absorbance values to determine 
the protein content within the WT and the EGFR vIII cell line. 
 
7.8.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is one of the major techniques in protein analysis, and here proteins are 
electrophoresed into a gel and separated based upon size and charge as they migrate through 
the gel. Smaller proteins characteristically migrate through the gel faster than larger protein.  
The sample buffer is made up by TRIS, SDS, BTB and mercaptoetanol. The Sample buffer 
was added to the cell lysate samples by a factor of 1:4, before they were heated for 5 minutes 
at 95oC. To ensure an appropriate mix the samples were vortexed and sonicated for a few 
minutes. Finally, the solutions were centrifuged for 5 minutes to avoid that impurities within 
the samples were added to the gel.  
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The polyacrylamide gels used to separate the sample proteins was made and run using a 
BioRad “mini-gel” system. The gels consisted of a 4% acrylamid stacking gel and a 10% 
acrylamid separation gel and were 1 mm tick. The two components of the gel have different 
tasks; the upper stacking gel compresses the added samples into thin layers, while the lower 
separation gel function to separate the proteins according to size. The chosen acrylamid 
content depends on the size of the protein to be identified in the sample. The smaller the 
known weight, the higher acrylamide percentage should be used. As references for the added 
protein samples a “BioRad Precision Plus Protein All Blue Standard” (protein standard) and a 
“Invitrogen MagicMark XP Western Protein Standard” (western blot standard) were added to 
each gel. The gel electrophoresis was run at room temperature at 200V in 1x running buffer. 
The electrophoresis was carried out until the lower molecular weight proteins had diffused 
through the gel. This was observed using the added protein standard. The approximate 
running time was 90 minutes.  
 
Figure 7.1 The procedure for SDS-PAGE and Western blotting. The presented illustration is taken from 
ScienceSlides, PowerPoint.  
 
7.8.3 Western blotting 
When identifying the proteins, specific antibodies are used to detect their antigen. Because of 
the specificity within antibody-antigen interaction, a single protein may be identified in a 
welter of protein mixture. Usually western blotting is used to positive identify a protein within 
a complex sample. 
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Following SDS-PAGE the gel is translocated into transfer buffer where it is kept for 10 
minutes. By using a BioRad tank transfer system the proteins are translocated onto a 
nitrocellulose membrane. The procedure was run at 4oC and at a constant voltage (19V, 2 
ampere) for 12 hours. Afterwards, the membrane was transferred to a TBS-T–MLK blocking 
solution at room temperature for 2 hours to avoid unspecific binding of antibodies. When the 
blocking was completed the primary antibody diluted in TBS-T–MLK was added and the 
membrane was incubated at 4oC overnight. The membrane was rinsed for 10 minutes using 
TBS-T–MLK and for 3 x 10 minutes in TBS-T before addition of the secondary antibody 
(also diluted in TBS-T–MLK). At last the membrane was washed 3 x 10 minutes in TBS-T 
before stored in milliQ. 
When detecting the protein bound antibodies, the membrane was removed from the milliQ 
and added detection reagent A and B, before incubated at room temperature for 1 minute. A 
Bio-Rad Fluor-S multiimager was used for imaging and QuantityOne computer software for 
analyzing. 
 
A Ponceau–S red staining solution was added to the membranes to verify a successfully 
transfer of proteins to the membrane. Here the blots were stained in the Ponceau-S red 
solution for 30 seconds before they were rinsed using milliQ. Finally scanned images of the 
blots were taken.   
 
7.8 Immunostaining for imaging  
Cells were trypsinated and collected as previously described. Approximately 50.000 cells 
(measured pre volume) were translocated to a culture dish with a fitted cover slip, 2 ml culture 
media were added and the cells were grown over night at 37oC / 5% CO2 in a cell incubator. 
Next morning 2µl 100µM mito tracker deep red (MRDR) (final concentration of 0.1 µM) 
were added and the cells were incubated at 37oC/ 5% CO2 for 30 minutes. The cells were 
gently rinsed using previously heated culture medium lacking phenol red supplied with 10% 
FBS. Afterwards the cells were added 1ml culture medium lacking phenol red and imaged 
using a Zeiss LSM 510 Meta confocal microscope connected to Ultra View computer 
software. The images were processed using ImageSuite software.  
  Results 
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8. Results 
 
8.1 Characterization of cell models 
The two cell lines used in these experiments were U87 WT and U87 EGFR vIII isolated from 
human glioblastoma. To determine that the EGFR vIII expression indeed was elevated in the 
modified U87 glioma cell line (U87 EGFR vIII), we measured the EGFR vIII expression 
using flow cytometry and western blotting. 
 
Figure 8.1. Results of EGFR antibody staining by flow cytometry. The dilution of the EGFR vIII antibody 
was 1:200 and the dilution of the anti-mouse APC secondary antibody was 1:5000. The curves shown are for 
unstained control cells, cells stained with a secondary antibody only, and cells stained with a primary and a 
secondary antibody for EGFR vIII and WT cell lines. 
 
The curves presented in figure 8.1 show the content of stained EGFR vIII protein within the 
different samples. The curve for the EGFR vIII cells stained with both primary and secondary 
antibody is displaced (dark blue) compared to the remaining samples, showing a raised EGFR 
expression for the manipulated cells.  
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The results determined by the Western blots confirm the observations found by flow 
cytometry. As seen in figure 8.2 the four wells containing proteins from the mutated cells 
(well 4, 5, 8 and 9) show a defined expression pattern for EGFR vIII. We can also see that the 
wells containing 60µg proteins/well (well 8 and 9) have a stronger signal compared to wells 
containing 40µg proteins/well (well 4 and 5). 
To confirm equal protein loading for each sample it is common to use the ubiquitously 
expressed actin as a marker. Here we used the dazo sodium salt Ponceau-S to check the 
protein levels. This was done since the size of EGFR vIII was 140 kDa and the SDS-PAGE 
was run such that the actin bands were no longer present on the gel for detection.  
 
 
Figure 8.2. Expression of EGFR vIII in WT versus mutated cells.  
U87 WT and EGFR vIII cell were lysed and protein content determined. For further calculations see appendix 
page 1. Afterwards the whole cell lysates were separated on SDS-PAGE, followed by immunoblotting using an 
EGFR vIII antibody. Two parallels were carried out, both presenting the same trend. (A) The western blot image 
was taken using a Bio-Rad Fluor-S multiimager. Two different protein concentrations were loaded to the gel 
together with a BioRad Precision Plus protein all blue protein standard and an Invitrogen MagicMark XP 
western protein standard. The blot was stained with EGFR vIII antibody diluted to a final concentration of 1:500, 
blocked with TBS-T/Mlk before stained with the anti-mouse horshradish peroxidase conjugated secondary 
antibody diluted 1:5000. 
(B) Scanned image of the blot after Ponceau–S red staining. 
 
Both the results found by flow cytometry and western blotting show an increased expression 
of EGFR vIII protein in the EGFR manipulated cells (EGFR vIII) compared to the WT. The 
Ponceau-S staining confirmed that the difference seen in EGFR vIII expression was not due to 
unequal protein loading in the western blot experiment. 
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Mitochondrial morphology in WT versus U87 EGFR vIII glioma cells  
Confocal images were taken to see whether increased expression had an impact on 
mitochondrial morphology. These images were studied for obvious visual differences 
between the two cell lines (Figure 8.3 and 8.4). In both cell lines the mitochondria were 
distributed mainly around the nucleus, furthermore the mitochondrial network was 
filamentous rather than fragmented. No obvious differences between the WT and the EGFR 
vIII overexpressing cells were found.   
 
 
Figure 8.3. Images of U87 WT and EGFR vIII glioma cells. 50.000 cells were plated on a culture dish with a 
fitted cover slip and cultured over night at 37oC/5% CO2 in a cell incubator. Following morning the cells were 
stained with a final concentration of 100nM Mitotracker DEEP red (MTDR) for 30 minutes at normal culture 
conditions before the medium was exchanged for DMEM medium without phenol red. Images were acquired 
using a Zeiss LSM 510 Meta confocal microscope using a 63x immersion objective. 5 images were taken and 
examined for each cell line. The presented image is representative for the findings. (A/A’)  MTDR image (B/B’) 
Differential interference contrast (DIC) image (C/C’) Overlay.  
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8.2 Metabolic profiling 
Oxygraph data 
Oxygraph measurements were carried out to look for possible differences in the respiratory 
capacity between the two cell types. These results are presented in figure 8.4. From these data 
a higher routine activity and maximum respiratory capacity was observed for the WT 
compared to EGFR vIII cells. These measurements also showed that the WT cell line used a 
smaller fraction of its maximum respiratory capacity under normal conditions. 
 
Figure 8.4. Metabolic data obtained from oxygraph measurements. Here Routine indicates the cellular 
respiratory capacity under normal conditions when glutamate and malic acid are present. Leak is O2 flow gained 
from protons entering the mitochondria through alternate channels than the ATP driven complex V. This is 
measured by adding the complex V inhibitor oligomycine. Max respiratory capacity is determined by adding the 
uncoupler FCCP. The contribution from complex II is measured by adding the complex I inhibitor rotenone. 
Maximum complex I capacity is calculated by subtracting the Complex II O2 flow from maximum respiratory 
capacity. The second diagram show how much of the maximum capacity the cells use under normal conditions 
by dividing the routine capacity on maximum respiratory capacity. These results were acquired using an 
Oroboros Oxygraph-2k. 
 
 
Lactate secretion  
Lactate is an indicator product of anaerobic glycolysis. We measured the amount of lactate 
secreted by the two different cell models under normal conditions. According to figure 8.5 
EGFR vIII cells show a 15-35 % raise in lactate production compared to the WT cell line 
which may indicate an increased glycolytic activity within EGFR vIII cells. Further results 
and calculations can be seen in the appendix page 2 
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Figure 8.5. Lactate production in U87 WT and U87 EGFR vIII cells. The cells were counted and the lactate 
secretion was determined using culture medium in which the cells had been grown in for 48 hours. A number of 
lactate standards and different dilutions of the culture media were plated in a 96 welled plate before the 
absorbance were measured using an ELx808 Ultra Microplate Reader. The lactate assays was carried out using 
medium from two distinct dates, hence 1.run and 2.run. The results are shown as relative percent values of the 
WT values for each run.  
 
8.3 Proliferation and the metabolic interactions. Evaluation of the 
proliferation assays  
Cell proliferation assays 
The observed variations in lactate secretion and respiration for WT and manipulated cells 
suggested that EGFR may regulate energy metabolism. To see if this also affects cell growth 
we investigated if there was a correlation between cell proliferation and EGFR vIII 
expression. Three effective and well known assays were used to determine the proliferation 
properties of the cell lines; MTT, BrdU and AlamarBlue. These assays employ different 
analytical principles (see matherials and methods) which may give additional information 
about the physiological status of the cell population. For these studies 3T3 fibroblast cells 
were used as a reference cell line. In addition to compare the proliferation patterns these data 
were used to determine the most suited cell density for further analyses. 
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Figure 8.6. Results of the MTT and BrdU proliferation assay. The cells were plated with different cell 
densities (1000 – 15000 cells/well) in a flat-bottomed 96-welled plate and kept for 24 hours at 37oC/5% CO2 in a 
cell incubator. The proliferation assays were accomplished according to the manufactory instructions and the 
absorbance was determined using an Asys UVM340 ELISA reader (MTT was measured at 570nm, while BrdU 
was measured at 370nm with a reference wavelength at 492nm). Four parallels of each sample were plated and 
the average of these parallels is shown in the diagram.  
 
Using the fact that proliferation correlates with absorbance in these assays, the data above 
show a cell density dependent increase in proliferation for all the three cell lines. Data from 
the MTT assay show a slightly higher proliferation rate for the WT cells, while EGFR vIII 
had a higher rate using the BrdU assay. For both assays 3T3 cells had lower proliferation rates 
than the U87 cells. 
 
Alamarblue has dual properties and can be measured by either fluorescence or absorbance. 
Here, both characteristics were tested and the proliferation trends compared. The absorbance 
was measured for the three cell lines after 2, 3, 4 and 24 hours, by reading at the two different 
wave lengths 570 nm and 600 nm.  
 
The fluorescent properties were determined 4 hours after AlamarBlue addition. As seen in 
figure 8.8A the U87 glioma cells (WT and EGFR vIII) seem to have higher activity compared 
to the fibroblast cell line. As for the absorbance measurements the fluorescence raises with 
increased cell number. 
 
The absorption data found are shown in Figure 8.8 B, C, and D. All three cell lines displayed 
a cell number and time dependent increase in the signal following 2-4 h of incubation. 
However, after 24 h the maximum Alamarblue signal was reached with the higher cell 
numbers, as seen by the cell density dependent flattening of the curve.  
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Figure 8.7. Results of the AlamarBlue assay. The cells were plated with different cell densities (1000 – 15000 
cells/well) in a flat-bottomed 96-welled plate and incubated for 24 hours at 37oC/5% CO2 in a cell incubator. 
(A) fluorescent analysis at 4 hours after AlamarBlue addition. Absorbance measurements were carried out at 
 2 (blue), 3 (pink), 4 (red) and 24 (green) hours after AlamarBlue addition respectively. % reduced AlamarBlue 
were calculated using equation 8.1. (B) % reduced AlamarBlue of 3T3 cells, (C) % reduced AlamarBlue of U87 
EGFR vIII cells and (D) % reduced AlamarBlue of U87 WT cells. Four parallels of each sample were plated and 
the average of these parallels is shown in the curves. 
 
To compare the three different assays the proliferation data were put into the same diagram. 
Here the values are relative to the maximum value at 15000 cells for its respective 
proliferation assay. According to the curves in figure 8.8, the proliferation assays show the 
same trend when using MTT, BrdU or AlamarBlue.   
  Results 
 48
 
Figure 8.8. Relative values of MTT, BrdU and AlamarBlue proliferation assays. For each cell line the data 
from the three assays were put into the same diagram. The AlamarBlue absorbances are from the 4 hour 
experiment. (A) Relative proliferation values for EGFR vIII, (B) WT and (C) 3T3 cell line respectively. 
 
Once the proliferation characteristics had been found, these data were used to determine the 
most suitable cell number for further trials. This concentration has to be in an area where the 
proliferation curves are linear. These conditions are favourable because they indicate a 
constant proliferation with a low fraction of apoptosis and abundant levels of nutrients are 
present. According to these data such conditions exist in the range between 3000 and 7000 
cells/well. Consequently, we chose to use 4000 cells/well for further experiments. 
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8.4 Effects of metabolic manipulation on cell proliferation 
Rotenone treatment 
Having determined the proliferation properties of the cells, we then asked whether the WT 
and manipulated cell line had differences in the metabolic regulation.   
Rotenone is an inhibitor of complex I in the Electron transport chain (ETC). The rotenone 
sensitivity is an indicator of how the cells depend on respiration for energy production. 
Rotenone treatment may also show the cellular ability to switch to an alternate energy 
pathway when the mitochondrial respiration is inhibited. 
 
These trials were used to find the rotenone concentration in which 50% of the proliferation 
was inhibited (IC50).To determine the IC50 value we used the MTT and BrdU proliferation 
assays. 
 
Cells were treated with rotenone concentrations ranging from 0.05-10µM. The 10µM 
concentration was used to fully “shut down” the contribution from complex I in the ETC. 
Despite similar experimental conditions, major variations in mitochondrial blockage response 
were observed for the three accomplished experiments. A metabolic interaction between MTT 
and rotenone was suspected, making MTT an inappropriate assay for proliferation 
measurements on rotenone treated cells. One of the experiments is shown in figure 8.9. 
 
 
 
Figure 8.9. Curves of rotenone treated cells using MTT proliferation assay. 4000 cell/well were plated in a 
flat-bottomed 96-welled plate and cultured for 24 hours at 37oC/5% CO2 in a cell incubator. The cells were then 
treated with different rotenone concentrations of 0.05µM, 0.1µM, 0.25µM, 0.5µM, 1µM and 10µM and stored 
for 20 hours at 37oC/5% CO2. Four parallels of each sample were plated and the average of these parallels is 
shown in the diagram. 
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Since MTT failed to function as appropriate assay for rotenone treated cells, BrdU was the 
only proliferation assay used for further rotenone analyses. The same rotenone concentrations 
as for MTT were used to inhibit the mitochondrial respiration.  
These trials were carried out 5 times, but due to experimental problems, the mean of 3 
successful experiments are shown in figure 8.10. From these data we see a significant 
difference in rotenone sensitivity. The EGFR vIII cells are more affected by respiratory 
blockage and have an IC50 value at approximately 0.1µM rotenone. According to these 
findings WT and 3T3 cells are more resistant to the rotenone treatment with an IC50 value at 
approximately 1µM.  
 
Figure 8.10. Determination of EGFR vIII rotenone IC50 value. 4000 cell/well were plated in a flat-bottomed 
96-welled plate and incubated for 24 hours at 37oC/5% CO2 in a cell incubator. The cells were then treated with 
different rotenone concentrations of 0.05µM, 0.1µM, 0.25µM, 0.5µM, 1µM and 10µM and stored for 20 hours at 
37oC/5% CO2 in a cell incubator. Four parallels of each sample were plated and the average of these parallels is 
shown in the diagram. All values are shown as relative percent values of the untreated control cells.  
 
 
2DG treatment  
Since rotenone treatment indicated differences in the mitochondrial respiration, we wanted to 
look at proliferation response when blocking the glycolytic energy pathway. Here the U87 
cells were treated with the hexokinase inhibitor 2-deoxy glucose (2DG), using concentrations 
within the range 0.15 - 10µM.   
Three experiments were accomplished and are shown in figure 8.12. Here, two experiments 
were carried out at high 2DG concentrations and one representative curve is presented. Here 
the proliferation rate increased before a sudden drop was seen. The instant fall made it 
difficult to determine the 2DG IC50 value and therefore an experiment at lower 2DG 
concentrations were carried out. Using data from the third experiment, the IC50 value of the 
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EGFR vIII cells was found to be approximately 1 µM 2DG. From these trials the WT and the 
EGFR vIII cells show a similar response to 2DG inhibition of the glycolysis. 
Figure 8.11. Determination of EGFR vIII 2DG IC50 value. 4.000 cell/well were plated in a flat-bottomed 96-
welled plate and kept for 24 hours at 37oC/5% CO2 in a cell incubator. The cells were then treated with different 
2DG concentrations (0.34µM, 1.6µM, 3.34µM, 4.66µM, 6.67µM and 10µM presented in A., 0.15µM, 0.3µM, 
0.6µM, 1.0µM, 1.5µM and 3µM in experiment B.) and stored for 20 hours at 37oC/5% CO2 in a cell incubator. 
Six parallels of each sample were plated and the average of these parallels is shown in the diagram. 
 
8.5. Effect of rotenone and 2DG treatment on lactate secretion  
In the previously experiments the EGFR vIII IC50 concentrations for rotenone and 2DG were 
determined. Further, we wanted to see whether these treatments could affect the lactate 
secretion in a different manner between the two cell lines cells. The lactate concentration were 
determined in WT and EGFR vIII control cells and in cells treated with 0.5µM 2DG, 1µM 
2DG, 500nM rotenone and 0.1µM rotenone.  
 
Figure 8.12 Lactate measurement of 2DG and rotenone treated cells. The cells were grown in a culture flask 
for 24 hours before treated for another 24 hour with rotenone or 2DG. During this time the flasks were kept at 
37oC/5% CO2 in a cell incubator. Further, culture medium was collected for lactate analysis. A number of lactate 
standards and different dilutions of the culture media were plated in a 96 welled plate before the absorbance 
were measured using an ELx808 Ultra Microplate Reader. The results are shown as relative percent values of the 
WT control. 
 
  Results 
 52
Upon glycolytic inhibition by 2DG, the lactate secretions by WT cells are approximately the 
same as control, while the mutated cell line shows a minor decrease. When blocking the 
respiration energy supply by rotenone, the lactate production is raised for both cell lines. This 
experiment show an elevated EGFR vIII secretion of lactate compared to WT cells when 
treated with rotenone. Further results and calculations can be seen in the appendix page 4 
 
8.6 Effects of metabolic inhibitors on proliferation related signalling 
Determination of protein signalling using antibodies 
Based on the above findings it was interesting to investigate factors that may connect 
regulation of cell proliferation with metabolism. We chose to study the expression patterns of 
common signalling pathways found in cancer cells. Here represented by Akt, AMPK α, 
AMPK β and ACC proteins, which are all involved in regulating cellular metabolism and 
energy production.  
 
Figure 8.13. Expression and activation of Akt in fixated U87 WT and EGFR vIII cells.  The cells were 
grown in a culture flask for 24 hours before treated for another 24 hour with rotenone or 2DG. During this time 
the flasks were incubated at 37oC/5% CO2 in a cell incubator. Furthermore, the cells were fixated using 3.7% 
formaldehyde. Measurements were carried out using three different primary antibodies, anti-Akt (total), anti-
phospho-Akt (Ser 473) and anti-phospho-Akt (Thr 308). 0.5·106 cells were used for each sample and one 
antibody was measured at the time. The primary antibodies were added to a final concentration of 1:100. After a 
60 minutes incubation time, a secondary antibody was added to each sample before measured using a BD 
FACSCalibur™ flow cytometer. The presented data are normalized relative to the WT control.   
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Akt expression and phosphorylation 
The pro-survival Akt protein is often found to be overexpressed in malign cells. By staining 
specific antibodies for the Akt phosphorylation sites we could assess how much of the 
expressed protein was phosphorylated.  
 
As seen in figure 8.13, after one day of rotenone and 2DG treatment, the Akt level was 1.6 
fold higher in EGFR vIII cells compared to WT cells. However, the Akt expression was 
increased in both 2DG and rotenone treated WT cells. The Akt levels after 2DG treatment 
were similar in the two different cell lines, since EGFR vIII cells remained unchanged. On the 
other hand, rotenone tended to increase the Akt expression in the EGFR vIII cells as well. The 
most elevated Akt expression is seen for the EGFR vIII cells treated with 500nM rotenone. 
Here a 1.6 fold increase compared to the WT cells is seen. 
 
To be activated, Akt depend on phosphorylation at its two phosphorylation sites, the 
regulatory domain at serine 473 and the kinase domain at threonine 308. Despite an elevated 
Akt expression the amount of active Akt decreases as seen in figure 8.13 B and C. Overall the 
WT cell line contain more phosphorylated Akt than the EGFR vIII. The two cell lines respond 
similarly to 2DG treatment, and displayed a dose dependent tendency of decrease in Akt 
phosphorylation at both Ser 473 and Thr 308. Although rotenone also gave reduced 
phosphorylation at these sites in both cell lines, the response was more pronounced for the 
Akt Thr 308 site in the EGFR vIII cells. This may indicate regulatory changes in these cells. 
 
AMPK expression and phosphorylation 
AMPK is a protein working as a sensor of cellular energy, and is activated upon nutrient 
deprivation, low energy status and stress. The protein is a heterotrimer and depends on all the 
three subunits α, β and γ for activation.  
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Figure 8.14.  Expression and activation of AMPK α/AMPK β in fixated U87 WT and EGFR vIII cells. The 
cells were grown in a culture flask for 24 hours before treated for another 24 hour with rotenone or 2DG. During 
this time the flasks were cultured at 37oC/5% CO2 in a cell incubator. Furthermore, the cells were fixated using 
3.7% formaldehyde. Measurements were carried out using four different primary antibodies, anti-AMPK α, anti-
phospho- AMPK α (Thr 72), anti-AMPK β and anti-phospho-AMPK β (Ser 108). 0.5·106 cells were used for 
each sample and one antibody was measured at the time. The primary antibodies were added to a final 
concentration of 1:50 (1:100 for the anti-phospho-AMPK β (Ser 108) antibody). After a 60 minutes incubation 
time, a secondary antibody was added to each sample before measured using a BD FACSCalibur™ flow 
cytometer. The presented data are normalized relative to the WT control. 
 
From the experiment where the expressions of the catalytic AMPK α subunit were measured, 
minor differences were observed. Compared to the WT control cell line the AMPK α 
expression was slightly higher for the 2DG treated EGFR vIII cells, while a decreased 
phosphorylation was seen in WT cells treated with 2DG and low concentration (0.1µM) 
rotenone. 
Examination of the phosphorylation site at the AMPK α subunit indicates the activation state 
of the subunit. According to our observations (Figure 8.14), 2DG did not affect AMPK α 
activation. When treated with low rotenone concentrations (500nM) a minor drop in Thr 172 
phosphorylation was observed for both cell lines. A 1.4 fold increase in AMPK α activation 
was seen for the 0.1µM rotenone treated WT cells while the EGFR vIII showed similar 
properties as the control cells. 
Furthermore, expressions of the glycogen binding AMPK β subunit were measured. As shown 
in Figure 8.14 C, the treated cells had a similar or raised expression of the subunit compared 
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to control cells. EGFR vIII cells had an elevated expression of the subunit after treatment with 
1µM 2DG or rotenone. Especially after rotenone treatment, the effect was more pronounced 
in the EGFR vIII cells. 
As our previous data on AMPK α activation, the amount of activated AMPK β were at similar 
levels in the two cell types, and remained unchanged after the treatments. 
 
ACC expression and phosphorylation 
ACC is a regulator of fatty acid oxidation and is located downstream of AMPK in the 
metabolic cascade. AMPK phosphorylation increases the phosphorylation of ACC and 
deactivates it enzymatic activity. 
 
Figure 8.15. Expression and activation of ACC in fixated U87 WT and EGFR vIII cells. The cells were 
grown in a culture flask for 24 hours before treated for another 24 hour with rotenone or 2DG. During this time 
the flasks were kept at 37oC/5% CO2 in a cell incubator. Furthermore, the cells were fixated using 3.7% 
formaldehyde. Measurements were carried out using two different primary antibodies, anti-ACC and anti-
phospho-ACC (Ser 79). 0.5·106 cells were used for each sample and one antibody was measured at the time. The 
primary antibodies were added to a final concentration of 1:400 for the anti-ACC and 1:25 for the anti-phospho-
ACC (Ser 79). After a 60 minutes incubation time, a secondary antibody was added to each sample before 
measured using a BD FACSCalibur™ flow cytometer. The presented data are normalized relative to the WT 
control.   
 
The untreated WT and EGFR vIII cells have similar ACC expression and phosphorylation 
properties due to our observations. These findings also demonstrated that the expression and 
activation of ACC in the glioma cells were unaffected by 2DG and rotenone treatment (Figure 
8.15 A and B). 
  
8.8 Use of fluorescent probes to determine mitochondrial properties  
Our experiments on protein signalling and metabolic regulation showed some variations 
between the two cell lines. Therefore, we wanted to look for correlations between our 
previous results and mitochondrial properties that are often affected in cancer cells. The 
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characteristics investigated were mitochondrial mass, mitochondrial membrane potential and 
ROS production.  
 
NAO - Nonyl Acridine Orange 
NAO binds selectively to the cardilipin lipid in the inner mitochondrial membrane and can be 
used for determination of mitochondrial mass within cellular samples. 
 
Figure 8.16. Results from NAO measurements of rotenone and 2DG treated cells. The cells were grown in a 
culture flask for 24 hours before treated for another 24 hour with rotenone or 2DG. During this time the flasks 
were incubated at 37oC/5% CO2 in a cell incubator. NAO was added to 0.5·106 cells to a final concentration of 
200nM. As a control FCCP was added to one of the samples to a final concentration of 0,2mM. Fluorescent 
measurements were carried out at a BD FACSCalibur™ Flow Cytometer and detected in FL-1 (A) NAO stained 
control cells for WT and EGFR vIII  (B) NAO stained WT cells (C) NAO stained EGFR vIII cells. 
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The measured mitochondrial mass for the untreated control cells are shown in figure 8.16 A. 
Here, the presented findings suggest a higher content of mitochondria in EGFR vIII cells 
compared with WT cells.  
The treated WT cells have an elevated mitochondrial mass compared to the control cells 
according to the results presented in figure 8.16 B (when comparing the geometric mean 
values). The curves indicate a possible bimodal cell population within the WT cell line, and 
must be investigated in more detail. Here EGFR vIII cells show a different behaviour (Figure 
8.16 C). The 2DG treated cells have an unaffected mitochondrial mass while a decreased 
mitochondrial content are observed for the rotenone treated EGFR vIII cells.  
 
TMRM - Tetramethyl Rhodamine Methyl Ester  
The most common probe used to determine mitochondrial membrane potential (ΔΨm) is the 
fluorescent probe TMRM. 
In this experiment we observed an enhanced ΔΨm in untreated EGFR vIII control cells when 
compared to the WT control (Figure 8.17 A). Here, the geometric mean values of the mutated 
control are approximately twice as high as the WT. Using these data from Figure 8.17 B and 
C, we observed that the ΔΨm for both cell lines were unaffected by metabolic inhibitors. The 
uncoupler FCCP was also added as a control of low membrane potential. This addition did not 
have the desirable effect, maybe because the FCCP concentration was to low. 
 
ROS - CM2H2DCFDA 
ROS are implicated in cell signalling and metabolism, and are considered to play major roles 
as carcinogens. The mitochondria are major producers of ROS within the cells, and we here 
wanted to measure ROS levels using CM2H2DCFDA as detecting probe. 
As seen in figure 8.18 A, our measurements indicate possible differences in ROS 
concentrations between the two cell lines. From the geometric mean calculations we can see 
elevated ROS concentration within the EGFR vIII cells compared to the WT. When treated 
with 2DG the WT cell line have an increased ROS production, while rotenone treatment does 
not have an obvious effect on ROS (Figure 8.18 B). Upon rotenone treatment, the ROS 
production in EGFR vIII cells decreases with elevated rotenone concentration. A minor 
reduction in ROS concentration is also seen for the 2DG treated EGFR vIII cells (Figure 8.18 
C). 
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Figure 8.17. Measurements of mitochondrial membrane potential (ΔΨm) in rotenone and 2DG treated 
cells. The cells were grown in a culture flask for 24 hours before treated for another 24 hour with rotenone or 
2DG. During this time the flasks were kept at 37oC/5% CO2 in a cell incubator. TMRM were added to 0.5·106 
cells to a final concentration of 200nM. As a control FCCP was added to one of the samples to a final 
concentration of 0,2mM. Fluorescent measurements were carried out at a BD FACSCalibur™ Flow Cytometer 
and detected in FL-2. (A) TMRM stained control cells for WT and EGFR vIII  (B) TMRM stained WT cells (C) 
TMRM stained EGFR vIII cells. 
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Figure 8.18. Measurements of ROS concentrations in rotenone and 2DG treated cells. The cells were grown 
in a culture flask for 24 hours before treated for another 24 hour with rotenone or 2DG. During this time the 
flasks were incubated at 37oC/5% CO2 in a cell incubator. CM2H2DCFDA was added to 0.5·106 cells to give a 
final concentration of 5µM. As a control H2O2 was added to one of the samples to a final concentration of 
100µM. . Fluorescent measurements were carried out at a BD FACSCalibur™ Flow Cytometer and detected in 
FL-1.   
(A) ROS stained control cells for WT and EGFR vIII  (B) ROS stained WT cells (C) ROS stained EGFR vIII 
cells. 
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9. Discussion 
 
The aim of the study was to determine if EGFR mediated signalling represents a possible 
regulatory link between cellular proliferation and energy metabolism. This theory was 
investigated by comparing a cell line having constitutively active EGFR signalling with wild 
type cells. The cells were challenged with selective modulators of energy metabolism, and 
several characteristics describing physiological and biochemical properties were analysed.  
 
Our data indicate possible metabolic variations between the cell lines, with the WT cells 
having an elevated respiratory capacity while the EGFR vIII cells show an enhanced 
glycolysis, which is consistent with the level of aggressiveness for the two cell lines [14, 15]. 
Mitochondrial characteristics such as mitochondrial mass, mitochondrial membrane potential 
and ROS production also seem to be raised for the mutated cells. No distinct difference in 
proliferation properties were observed for the two cell lines under normal cellular conditions. 
Upon energy deprivation, rotenone treatment had a stronger inhibitory effect on proliferation 
in EGFR vIII cells, while 2DG treatment had a similar effect on EGFR vIII and WT 
respectively. This study also discovered possible difference in cellular stress response and 
intracellular signalling.  
 
When characterizing the cells we measured the occurrence of mutated EGFR vIII protein 
within the two cell lines to ensure a difference in protein expression. By the use of flow 
cytometry and western blot analysis we confirmed over-expression of the EGFR vIII protein 
in the mutated cells compared to the WT. These methods are well established to confirm 
protein expression [64]. An advantage with flow cytometry is that it is less time consuming 
compared to a western blot. Western blotting on the other hand represents a more specific 
antibody binding. 
 
The three proliferations assays used in this study, BrdU, alamarBlue and MTT, use distinct 
cellular characters to determine cellular proliferation. BrdU measures cellular DNA synthesis 
by incorporating into the cellular DNA, whereas the alamarblue and MTT assays are based on 
different metabolic activities within living cells [65]. As cell characteristics may be disturbed 
upon gene manipulation [1], an absolute correlation can not be expected between the assays. 
This was observed in our experiments where some differences between the proliferation 
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assays were seen. The MTT assay indicated that the WT cells had a higher proliferation rate 
compared to the mutated EGFR vIII cell line, However, BrdU incorporation showed an 
enhanced proliferation for the EGFR vIII cells compared to WT. The final assay, alamarblue, 
resulted in similar proliferation properties for both the mutated and the WT U87 cells. All the 
three proliferation assays presents a higher proliferation rate for the U87 glioma cells than the 
3T3 reference cell line. These findings correlate to the fact that highly aggressive malignant 
cells have an abnormal proliferation compared to transformed cells [14]. Our results suggest 
that care should be taken when choosing proliferation assay, which is in line with previous 
observations [66]. 
 
Our data demonstrated a possible aberrant interaction between the MTT assay reactants and 
metabolic modulators such as rotenone (Figure 8.9). MTT is therefore an unsuitable assay for 
detecting proliferation properties in rotenone treated cells. A significant analytical variance 
was seen, and the lack of effect of rotenone was unexpected and not in correlation with the 
BrdU assay. Findings suggest that the MTT itself may affect cellular functions and conditions 
to some extent, causing some discordance of cell viability measurement [67]. This could be 
the fact, but at the same time our data on untreated cells seemed to correlate to the other 
proliferation assays. A possible explanation for these effects can be an interaction between 
rotenone and the MTT reaction system. Rotenone is an inhibitor of complex I in the ETC, 
while MTT has been suggest to be mainly reduced bymitochondrial, microsomal and 
cytosolic enzymes [68]. The MTT reduction process is not fully understood, and potentially 
mitochondrial reductases, such as complex I, can be involved in the reaction which can 
explain the possible interactions with rotenone [69]. It has been postulated that changes in 
metabolic activity can give large changes in MTT results even if the number of viable cells is 
constant [70]. 
Since alamarblue reduction is believed to be mediated, at least in part, by mitochondrial 
enzymes, the proliferation assay was excluded from further experiments on rotenone treated 
cells [71]. The data from the three assays did not suggested dramatic differences in 
proliferation between the two cell types. Based on the above discussion the BrdU assay was 
chosen in the following experiments. 
 
According to our results, the WT and 3T3 cells were more resistant to rotenone than the 
mutated cell line (Figure 8.10). EGFR vIII immediately responded to the added rotenone 
shown by a rapid decrease in cell proliferation, while higher rotenone concentrations are 
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needed to obtain the same effect in the WT and 3T3 cell line. According to our respiratory 
data the WT cell line had a higher routine respiration than EGFR vIII cells (Figure 8.5). 
Consequently we believed that the WT cells would be more affected by the respiratory 
blockage caused by rotenone. As this effect was not observed we hypothesise that the WT 
U87 glioma cells are capable of turning to glycolysis when respiratory energy is absent [72]. 
The fact that the EGFR vIII mitochondria show a more rotenone sensitive behaviour may 
indicate that the mutated cells lack the metabolic flexibility present in WT cells.   
 
Glycolytic blockage by 2DG produced a similar response in WT and mutated cells. In our 
findings we observed a raised lactate secretion for EGFR vIII cells, indicating an elevated 
glycolysis. 2DG inhibition has been reported to induce Akt phosphorylation at Thr 308 and to 
induce oxidative stress caused by ROS [73]. Being kept in a glucose rich culture media, 
glucose is the main nutrient source for the proliferating cells. Therefore, by blocking the 
glycolysis the pyruvate production needed for driving the citric acid cycle is inhibited [4]. As 
the citric acid cycle is the main supplier of NADH and succinate to the ETC, 2DG treatment 
will affect the ETC in an indirect manner. This effect could possibly be avoided by growing 
the cells in fat rich medium. Here, fatty acid oxidation would supply acetyl CoA to the citric 
acid cycle, and at the same time the actual glycolytic inhibition by 2DG could be measured.     
 
The EGFR vIII cell line appeared to have a lower respiratory reserve capacity (coupling), as 
shown by our oxygraph measurements (figure 8.5). This tells us that WT cells may have a 
higher respiratory potential that can be used when exposed to stress, while EGFR vIII, which 
under normal conditions, use respiration closer to its max capacity may be more sensitive to 
additional stress. Despite the variation in respiratory status, both WT and EGFR vIII seem to 
utilize both respiratory and glycolytic energy production to maintain their cellular ATP 
homeostasis. Protein expression patterns can govern this modulation ability as shown and 
reviewed in other studies [74, 75]. 
 
The aggressive tumor behaviour of EGFR vIII is presented by elevated proliferation, 
increased tumor volumes, down regulated apoptosis and a decreased response to 
therapeutically treatment compared to the WT cell line [76]. The increased lactate secretion 
seen within EGFR vIII cells support our respiratory findings. Lactate is a natural by-product 
of glycolysis under anaerobic conditions. However, highly glycolytic cancer cells secrete 
elevated levels of lactate even under aerobic conditions [14]. Measuring lactate secreted by 
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the cells gave us an indication of the glycolytic activity within the two cell lines. Based on our 
results the mutated cell line is more dependent on the glycolysis for energy production, while 
WT cells use mitochondrial respiration to a greater extent. These results correspond to the fact 
that aggressive cancers have raised glucose consumption [77].  
Our investigation of mitochondrial morphology indicates a filamentous mitochondrial 
network surrounding the nucleus in both cell types (figure 8.3). These preliminary 
experiments do not indicate that there is a change in mitochondrial localization or 
morphology upon EGFR vIII over-expression, however further analysis have to be made to 
confirm these results.   
 
Mitochondrial mass was measured using NAO which binds to cardiolipin in the mitochondrial 
matrix. Our experiment indicates an elevated mitochondrial content within EGFR vIII control 
cells compared to WT (Figure 8.16 A). Even if a higher mitochondrial level in was found 
EGFR vIII, this was not clear by the mito-tracker imaging. An extensive examination of 
mitochondrial biogenesis is needed to reveal a possible aberration [78].   
 
The NAO signal in 2DG treated EGFR vIII cells were unaffected compared to control, while 
it decreased for rotenone treated cells. As previously stated the mitochondria in EGFR vIII 
cells may have a reduced ETC capacity. The cells may try to make up for this by increasing 
mitochondrial biogenesis, giving a raised mitochondrial mass in mutated cells [79]. Impaired 
mitochondria can produce high levels of ROS [80], and by inducing more stress by rotenone 
treatment these mitochondria might reach a threshold where they are targeted for active 
degradation, so called mitophagy [81]. This is an active process in which damaged 
mitochondria are selectively removed from the cell by autophagy [81]. This can explain the 
decrease in NAO signal from rotenone treated EGFR vIII cells. These results correlate with 
the increased ROS production seen in EGFR vIII. Changes in EGFR vIII mitochondria may 
thus increase mitochondrial ROS production and thereby make these cells more sensitive for 
metabolic stress. Based on these results, we hypothesize that EGFR vIII contain a high 
number of deficient mitochondria, therefore production of ROS could be significantly 
increased upon rotenone treatment. Furthermore, the oxygraph measurements showed a 
reduced respiratory reserve capacity of the EGFR vIII cells compared to WT cells. These 
findings may also occur due to an increased number of deficient mitochondria in the mutated 
EGFR vIII cell line and strengthens the mitophagy hypothesis. 
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Under normal conditions ROS operates as intracellular signalling molecules [82]. High levels 
of ROS can be damaging to cellular compounds such as lipids, DNA and proteins [80]. 
Complex I and III in the ETC have been suggested to be the major ROS source in the 
mitochondria, and this ROS can readily influence the mitochondrial function [12]. 
Our studies indicate an elevated ROS production in the mutated EGFR vIII cells (Figure 
8.18). When examining the EGFR vIII cell line a decreased ROS production was seen upon 
rotenone treatment. A possible explanation for this behaviour can be the fact that ETC 
inhibition reduces ROS generation as have been suggested by previous studies [83]. 
Another possibility in ROS decrease can be due to mitophagy [81]. In EGFR vIII control cells 
the mitochondria may be damaged (due to mutations) and produce ROS, but are still operative 
enough to supply the cells with small amounts of ATP. When rotenone is added the 
mitochondria are pushed into an un-functional state where the cells decide to degrade the 
damaged mitochondria by mitophagy, hence leading to a reduced ROS production. 
 
Our findings indicate a higher mitochondrial membrane potential (ΔΨm) for the EGFR vIII 
cells compared to control, and in both cell lines the ΔΨm was unaffected by 2DG and 
rotenone treatment compared to their respective controls. ΔΨm reflects ETC activity and 
mitochondrial function [84], but when adding rotenone no major difference was seen. Studies 
have shown that cells with an enhanced intrinsic ΔΨm are better at handling hypoxia, 
avoiding apoptosis, initiate angiogenesis, show good growth properties under though 
conditions and have raised basement membrane invading properties [9]. Despite the fact that 
our experiments indicated similar proliferation properties for WT and EGFR vIII, these 
properties might change in vivo. 
 
The Akt protein is often overexpressed in malign cells where it among other properties acts as 
a stimulator of glycolysis and an inducer of apoptotic resistance [33]. 
Our study shows a higher expression of Akt for the EGFR mutated cells, especially under 
normal conditions. This may suggest that the EGFR vIII cells have increased survival 
signalling, but at the same time they are metabolically less flexible and therefore more 
sensitive to energetic stress induced by rotenone. As the cells are treated with reagents 
blocking their nutrient supply, they become more dependent on pro survival stimuli for 
survival [85]. Lacking the extracellular binding domain, the EGFR vIII has been suggested to 
be constantly activated leading to an increased activation of the Akt pathway [60].  
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In order to achieve its activated state, the two Akt phosphorylation sites (Ser 473 and Thr 
308) must be phosphorylated [41]. We observed a decreased phosphorylation status for the 
treated cells when compared to control, and this indicates a reduced Akt activation. WT cells 
have a higher Akt phosphorylation compared to EGFR vIII where Akt is almost knocked 
down.  
Upon Akt activation the regulatory domain Ser 473 is first phosphorylated while the 
phosphorylation of the Thr 308 kinase domain occurs second to the Ser 473 activation [41]. 
This is reflected in the phosphorylation patterns we observed from our anti-phospho flow 
experiment for these two phosphorylation sites. 
 
There seem to be a mechanism for raising the protein expression of Akt when the cells are 
treated with 2DG or rotenone, but according to the phosphorylation data less Akt is active.    
The protein Akt may be upregulated but not activated via phosphorylation. This could be a 
way for the cells to prepare itself for a scenario of enhanced stress. 
Akt expression is upregulated in EGFR vIII when treated with low rotenone concentrations, 
whereas the upregulation is lower in cells treated with high rotenone concentration. Damaged 
mitochondria produce ROS, but severely damaged mitochondria can be removed by 
mitophagy [81]. This could be the case here, where the high rotenone concentration triggers 
the mitophagy pathway and removes the detrimental mitochondria. Moreover it has been 
shown that ROS suppresses Akt activity [86] which correlates with our findings that EGFR 
vIII cells with high amount of ROS have less Akt activation.  
 
Figure 9.1 Suggested model of mitochondrial responses to treatment with energy suppressors.  
 
AMPK is a protein acting as a sensor for cellular energy status and is activated by nutrition 
deprivation and stress. The activated AMPK reconfigures the cellular metabolism from an 
energy consuming to an energy saving state [13]. AMPK is made up of three subunits with 
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the α-subunit being catalytic, the β-subunit containing a glycogen sensing domain and the γ-
subunit having AMP/ATP binding capacity [13]. In our experiments the expression and 
activity of the two AMPK subunits α and β were measured. Treatment with 2DG and 
rotenone had little or no effect on AMPK α protein expression. However, at the 
phosphorylation site Thr 172 of AMPK α, rotenone treatment gave a change in 
phosphorylation.  
For AMPK β, a slightly different expression pattern was seen. Here, the rotenone and 2DG 
treated cells present elevated protein levels.According to the Ser 108 phosphorylation site just 
a small increase in AMPK β activity is seen for the treated cells. The protein expression of 
AMPK β has a similar pattern as Akt, but under stress conditions a fall in Akt 
phosphorylation is seen while a minor raise in AMPK β activation occur. This behaviour can 
be explained from Figure 5.7 where Akt is seen to be an upstream inhibitor of AMPK. These 
findings correlate with previous experiments onMDA-MB-468 breast cancer cells [85]. 
 
ACC is a downstream enzyme of AMPK regulating the oxidation of fatty acids. Active 
AMPK phosphorylate and inactivates metabolic enzymes such as ACC [87].  
According to our findings, the ACC expression and activation is unaffected by 2DG and 
rotenone treatment. These results correspond to the findings of activated AMPK where minor 
changes in AMPK activation were seen. ACC staining was utilized as an indicator of AMPK 
activation [85] and a possible mismatch between AMPK and ACC activation could reveal 
experimental errors. 
 
Enhanced glycolytic activity is followed by high pyruvate concentrations and increased 
lactate production [3]. Under conditions where the energy supply is blocked, cells are forced 
to modify their metabolism in order to survive. From our measurements using 2DG and 
rotenone, different metabolic properties for WT and EGFR vIII were seen. EGFR vIII was 
most inhibited by 2DG treatment, while rotenone treatment gave a raised lactate secretion 
within both cell lines. These findings correlate to the hypothesis that aggressive tumors have 
an upregulated glycolysis [77]. The fact that WT cells are more resistant to 2DG may indicate 
that WT cells are more capable of switching between glycolysis and mitochondrial respiration 
as its main nutrient source. Under the given growth conditions WT seem to be better suited 
for survival compared to the EGFR vIII which has a higher dependence on glycolytic energy 
production. 
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10. Conclusions and future perspectives 
 
 
The results obtained from this study indicate different mitochondrial properties for U87 
glioma WT and EGFR vIII cells. The cell line containing the mutated EGFR vIII protein has 
previously been proven to present a more aggressive behaviour than the WT cell line. This 
statement correlate with our findings as an increased glycolytic activity and a decreased 
mitochondrial respiration within the EGFR vIII cells were observed. These characteristics are 
known to be hallmarks for aggressive cancer cells. 
Despite these metabolic modifications no obvious difference in proliferational behaviour were 
observed between the cell lines. This may be due to the fact that EGFR vIII have favorable 
properties within in vivo growing tumors [88], properties that are not present under these ex 
vivo given growth conditions. Therefore, a different proliferation pattern may have been 
found if the cells had been grown as spheroids or under in vivo conditions. 
EGFR vIII cells were found to be more sensitive to respiratory inhibition and we therefore 
suggest a possible defect in the respiratory system for this cell line. These findings were 
strengthend by our results showning elevated mitochondrial mass and ROS production within 
EGFR vIII cells. We hypothesize that to make up for the disturbed mitochondrial ATP 
production the cells elevate their mitochondrial biogenesis. This creates an enhanced 
production of ROS which may further damage the mitochondrial function. If the 
mitochondrial damage is too extensive, the unfunctional mitochondria can be degraded by 
mitophagy. 
We also found that upon energy blockage the U87 cells express higher levels of Akt and 
AMPKβ. A decreased phosphorylation for Akt was measured and this may also support our 
thesis as raised ROS concentration is a suppressor of Akt activity.  
 
The results in this study are based on data from a limited number of experiments, and some of 
the experiments will have to be repeated and/or expanded in order to be able to draw more 
firm conclusions. 
An exciting future objective would be to examine if EGFR vIII cells are more capable of 
modulating their metabolism when treated with a combination of glycolytic and respiratory 
inhibitiors than the WT cell line. 
To increase our knowledge on the metabolic role of EGFR vIII, we must examine other 
possible contributors in the metabolic regulatory system. Interesting targets for futher analysis 
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will be the protein synthesis regulator mTOR, the tumor suppressor p53 or the Ras-Raf-MEK-
ERK and JAK/STAT transcriptional pathways.  
 
To increase our understanding on mitochondrial dysfunction in cancer cells and their role in 
metabolic regulation, further studies must be carried out. A goal for the future must be to 
identify metabolic targets that can be used for clinical treatment.   
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12. APPENDIX  
 
 
12.1 Standard curve for protein determination used for western blotting 
  
A number of protein standards (BSA) with a protein content ranging from 0-2000µg/ml were 
made. The procedure was carried out as previously described in section 7.8.1. Two parallels 
were made for each sample and the mean value was used to draw a protein standard curve. 
Absorbance measurements were carried out at 563nm using an UVM340 ELISA reader. 
 
Protein standard 
(µg/ml) 
Absorbance 
parallel 1 
Absorbance 
parallel 2 Mean 
Mean – 
background (*) 
(*) 0 0,189 0,189 0,19 0 
25 0,212 0,213 0,21 0,02 
125 0,34 0,351 0,35 0,16 
250 0,481 0,475 0,48 0,29 
500 0,72 0,716 0,72 0,53 
750 1,023 1,069 1,05 0,86 
1000 1,328 1,301 1,31 1,13 
1500 1,761 1,728 1,74 1,56 
2000 1,963 2,029 2,00 1,81 
Table 12.1 Determination of protein content 
 
Standard curve protein determination
y = 229,84x2 + 641,51x + 25,014
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Figure 12.1 Standard curve for protein determination used for western blotting 
  
From the standard curve the equation: y = 229.84x2 + 641.51 + 25.014 was calculated. We 
used the equation to determine the protein content within our samples.   
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 Samples Samples - background 
y  = 229.84x2 + 
641.51 + 25.014 Dilution 
Protein content 
(mg/ml) 
Mean Protein 
content (mg/ml) 
2,211 2,02 2566,97 1 2,57 
2,217 2,03 2576,93 1 2,58 2,57(*) 
2,029 1,84 2272,85 2 4,55 
1,996 1,81 2221,15 2 4,44 4,49 
1,308 1,12 1257,33 5 6,29 
1,34 1,15 1297,34 5 6,49 6,39 
0,853 0,66 739,46 10 7,39 
0,81 0,62 695,44 10 6,95 7,17 
0,534 0,35 433,12 20 8,66 
WT 
0,553 0,36 450,06 20 9,00 8,83 
2,075 1,89 2345,75 1 2,35 
2,075 1,89 2345,75 1 2,35 2,35(*) 
1,57 1,38 1598,72 2 3,20 
1,568 1,38 1595,99 2 3,19 3,19 
0,946 0,76 837,57 5 4,19 
0,914 0,73 803,36 5 4,02 4,10 
0,601 0,41 493,58 10 4,94 
0,58 0,39 474,41 10 4,74 4,84 
0,328 0,14 260,16 20 5,20 
EGFR 
0,34 0,15 269,70 20 5,39 5,30 
Table 12.2 Determination of protein content in U87 glioma cells. (*) concentrations used for further analysis. 
 
12.2 Standard curve for lactate measurements in untreated cells 
 
5 lactate standards with the concentrations 4mM, 3mM, 2mM, 1mM and 0,5mM were made 
and the procedure was carried out as previously described in section 7.5. Two parallels of 
each sample were plated and measured using an UVM340 ELISA reader. The mean 
absorbance of the two parallels was used to make the lactate standard curve. (The plated 
samples were measured twice – before and after addition of LDH. The absorbances from the 
first measurement were subtracted from the second measurement, and these calculations are 
not shown.) 
 
Lactate standard 
(mM) 
Absorbance 
parallel 1 
Absorbance 
parallel 2 Mean 
Mean – 
background (*) 
(*) 0 0,300 0,352 0,326 0 
0,5 0,397 0,425 0,411 0,085 
1 0,464 0,497 0,481 0,155 
2 0,542 0,598 0,570 0,244 
3 0,732 0,770 0,751 0,425 
4 0,846 0,830 0,838 0,512 
Table 12.3 Absorbance determination of lactate standards   
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Standard curve for lactate determination
y = 0,1282x + 0,0124
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Figure 12.2 Standard curve for lactate determination in untreated cells 
 
The experiment was carried out using culture medium from two distinct dates, hence Run 1 
and Run 2. 
Run 1 Run 2 
Cell type Cell number Cell type Cell number 
EGFR vIII 1.17x106 cells/ml EGFR vIII  0.54x106 cells/ml 
WT 1.05x106 cells/ml WT 0.47x106 cells/ml 
Table 12.4 Cell number in the culture the medium was tapped from 
 
From the standard curve (Figure 12.2) the equation: y = 0,1282x + 0,0124 was calculated. We 
used the equation to determine the lactate concentration within our samples. 
 
 Absorbance 
parallel 1 
Absorbance 
parallel 2 
Mean 
absorbance 
y = 
0.1282x+0.0124 Dilution 
mM 
Lactate 
Mean lactate 
concentration 
2,808 2,884 2,52 19,56 1 19,56  
2,485 2,646 2,2395 17,37 2 34,74  
1,598 1,513 1,2295 9,49 5 47,47 50,17mM 
1,032 0,873 0,6265 4,79 10 47,90  
0,689 0,793 0,415 3,14 20 62,81  
EGFR 
vIII 
Run 1 
0,588 0,344 0,14 1,00 40 39,81  
2,755 2,889 2,496 19,37 1 19,37  
2,169 2,241 1,879 14,56 2 29,12  
1,179 1,196 0,8615 6,62 5 33,12 38,47mM 
0,726 0,814 0,444 3,37 10 33,67  
0,543 0,694 0,2925 2,18 20 43,70  
WT  
Run 1 
0,498 0,457 0,1515 1,09 40 43,40  
2,418 2,313 2,0395 15,81 1 15,81  
1,045 0,765 0,579 4,42 2 8,84  
0,805 0,806 0,4795 3,64 5 18,22  
0,609 0,599 0,278 2,07 10 20,71 21,69mM 
0,519 0,493 0,18 1,31 20 26,15  
EGFR 
vIII 
Run 2 
0,402 0,417 0,0835 0,55 40 22,18  
1,93 1,681 1,4795 11,44 1 11,44  
0,871 0,959 0,589 4,50 2 8,99  
0,721 0,703 0,386 2,91 5 14,57 13,19mM 
0,558 0,529 0,2175 1,60 10 16,00  
0,445 0,354 0,0735 0,48 20 9,53  
WT 
Run 2 
0,389 0,379 0,058 0,36 40 14,23  
Table 12.5 Determination of lactate secretion within untreated glioma cells. The mean of the lactate values 
presented in light grey were used to determine the lactate concentration within the used culture media.  
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12.2 Standard curve for lactate measurements in treated cells 
 
As for the lactate measurements for untreated cells, 5 lactate standards with the concentrations 
4mM, 3mM, 2mM, 1mM and 0,5mM were made and the procedure was carried out as 
previously described in section 7.5. Two parallels of each sample were plated and measured 
using an UVM340 ELISA reader. The mean absorbance of the two parallels was used to draw 
the lactate standard curve. Here a standard curve was made for each of the cell lines. (The 
plated samples were measured twice – before and after addition of LDH. The absorbance’s 
from the first measurement were subtracted from the second measurement, and these 
calculations are not shown.)  
 
Lactate standard 
(mM) 
Absorbance 
parallel 1 
Absorbance 
parallel 2 Mean 
Mean – 
background (*) 
(*) 0 0,34 0,37 0,36 0,000 
0,5 0,41 0,45 0,43 0,073 
1 0,50 0,53 0,51 0,158 
2 0,62 0,70 0,66 0,304 
3 0,79 0,86 0,82 0,466 
4 0,84 0,93 0,89 0,530 
Table 12.6 Absorbance determination of WT lactate standards   
 
Standard curve for WT cells 
y = 0,1381x + 0,0135
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12.3 Standard curve for lactate determination in treated WT cells 
 
Lactate standard 
(mM) 
Absorbance 
parallel 1 
Absorbance 
parallel 2 Mean 
Mean – 
background (*) 
(*) 0 0,33 0,38 0,36 0,00 
0,5 0,40 0,43 0,41 0,06 
1 0,45 0,49 0,47 0,11 
2 0,60 0,66 0,63 0,27 
3 0,62 0,75 0,69 0,33 
4 0,78 0,83 0,81 0,45 
Table 12.7 Absorbance determination of EGFR vIII lactate standards   
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Standard curve EGFRvIII cells
y = 0,1134x + 0,0057
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12.4 Standard curve for lactate determination in treated EGFR vIII cells 
 
From the standard curves (Figure 12.3 and 12.4) the equations; y =  0.1381x + 0.0135 (WT) 
and y = 0.1134x + 0.0057 (EGFR vIII) were calculated. We used the equations to determine 
the lactate concentrations within our samples. 
 
 Mean absorbance 
Parallel 1 and 2 
Equation 
(*) Dilution mM Lactate 
WT control 0,338 2,351 47,02
WT 2DG 0.5µM 0,370 2,580 51,61
WT 2DG 1µM 0,328 2,279 45,57
WT rotenone 500nM 0,496 3,495 69,90
WT rotenone 0.1µM 0,449 3,150 
20 
63,00
WT control 0,291 2,006 80,23
WT 2DG 0.5µM 0,261 1,789 71,54
WT 2DG 1µM 0,295 2,035 81,39
WT rotenone 500nM 0,418 2,930 117,21
WT rotenone 0.1µM 0,384 2,682 
40 
107,27
EGFR vIII control 0,372 3,233 64,66
EGFR vIII 2DG 0.5µM 0,307 2,657 53,14
EGFR vIII 2DG 1µM 0,327 2,830 56,61
EGFR vIII rotenone 500nM 0,429 3,730 74,60
EGFR vIII rotenone 0.1µM 0,465 4,053 
20 
81,06
EGFR vIII control 0,317 2,742 109,69
EGFR vIII 2DG 0.5µM 0,296 2,557 102,28
EGFR vIII 2DG 1µM 0,261 2,251 90,05
EGFR vIII rotenone 500nM 0,357 3,101 124,03
EGFR vIII rotenone 0.1µM 0,378 3,280 
40 
131,21
Table 12.8 Determination of lactate secretion within treated glioma cells. (*) For WT cells the equation “y = 
0.1381x + 0.0135” were used, while for EGFR vIII cells the equation “y = 0.1134x + 0.0057” were used. 
 
The same number of cells was plated before treatment with 2DG/rotenone and measurement 
of the lactate secretion.   
 
 
 
